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 ABSTRACT 
Kynurenic acid (KYNA), a metabolite of the kynurenine pathway, is emerging as a key 
factor in the development of psychotic disorders. Increased levels of KYNA are found 
in the brain and cerebrospinal fluid (CSF) of patients with schizophrenia and bipolar 
disorder, and are associated to psychotic symptoms. The unique pharmacological 
profile of KYNA allows it to exert actions on all the main neurotransmitter systems of 
the brain. The kynurenine pathway is under immunological control and can be induced 
by inflammatory signaling, hence linking findings of an immune involvement in 
psychotic disorders with established hypotheses of dopamine and glutamate in 
schizophrenia. KYNA has also been linked to impaired cognitive functioning, often 
accompanying psychotic disorders. Along this background, we set out to further 
investigate the kynurenine pathway and its induction by immune signaling, in the main 
psychotic disorders schizophrenia and bipolar disorder.  
Starting with a GWAS against CSF levels of KYNA, and with the aid of clinical 
association studies, post mortem analyses and cell culture experiments, we identified a 
gene variant associated to a decreased function of SNX7 in patients with bipolar 
disorder. SNX7 was shown to influence the activity of caspase-8, an activator of 
interleukin (IL)-1β. Using primary human astrocyte cultures, we show that IL-1β 
selectively induces TDO and hence increases the production of KYNA. In this study, 
KYNA was also associated to dopamine signaling, psychotic symptoms and impaired 
executive functions in patients with bipolar disorder. 
In patients with schizophrenia, we show that levels of CSF quinolinic acid (QUIN), 
produced in the other branch of the kynurenine pathway, are not elevated, but the 
QUIN/KYNA ratio is lowered. These findings suggest an imbalance in the upregulated 
kynurenine pathway in schizophrenia.  
Further tryptophan, along with the kynurenine metabolites KYNA and QUIN, the 
serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA), the dopamine metabolite 
homovanillic acid (HVA), and the cytokines IL-6, IL-8 and tumor necrosis factor 
(TNF)-α were investigated in the CSF of a cohort of twins with various psychiatric 
morbidity. Data presented here support a considerable environmental contribution to 
the levels of these factors. Associations between CSF levels of KYNA and levels of 
HVA as well as 5-HIAA were observed, as were associations between these CSF 
metabolites and psychopathology measures, extended to enlace schizotypal traits also 
present in relatives of patients with psychotic disorders. 
 Finally, we investigated if dermal ex vivo fibroblasts could serve as a model for 
studying the kynurenine pathway. All pathway enzymes were indeed expressed by the 
fibroblasts. KYNA was produced following stimulation with typical pathway inducing 
cytokines, i.e. interferon-γ and TNF-α, hence indicating the possibility to develop a 
model of easily accessible cells for studies of molecular and genetic aspects of 
psychotic disorders.  
Taken together, the data presented in this thesis strengthens the position of KYNA as a 
highly interesting target for further studies of psychotic disorders as well as for future 
therapeutic interventions. These data do not only confirm prior studies implicating a 
role for KYNA in psychotic disorders, but contributes with in-depth knowledge of 
potential molecular mechanisms linking a genetic makeup to aberrant immune 
signaling, CSF KYNA levels, psychotic symptoms and impaired cognitive function in 
patients with psychotic disorders. 
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1 INTRODUCTION 
Mental sickness has been, and still is, one of the most frightful and stigmatizing 
experiences a person can go through. Even in today's modern illuminated western 
society, people with mental illness are met by prejudice and fear, reactions that are 
normal and very humane when standing face to face with the different and unknown. 
The prejudice and fear are however not limited to the diseases per se. Few topics 
engage so many, and it is difficult to find a person who does not culture an opinion on 
the treatment of psychiatric diseases.  Opinions are frequently only in the form of a 
cautious apprehension, but all too often there is a fierce opposition to the methods used 
in modern psychiatry. This opposition needs to be faced by knowledge; a knowledge 
that can only spring out of research and evidence-based medical approaches, made 
available to the society. 
 
 
1.1 SCHIZOPHRENIA  
Even though descriptions of madness are as old as the written language, the German 
psychiatrist Emil Kraepelin was the first to describe the congregation of symptoms that 
later was to become known as schizophrenia (Kraepelin, 1919), portraying a disorder 
characterized by loss of reality perception. Since then, thousands of research reports 
regarding the symptomatology, etiology and molecular neurobiology have been added 
to this first report of the syndrome, but the disorder remains enigmatic. In the absence 
of biological markers, schizophrenia is defined by an observable clinical syndrome, 
comprising psychotic symptoms, social and emotional dissociation and diminished 
cognitive abilities. The symptoms can be classified into three rather distinct clusters 
(Andreasen and Olsen, 1982); Positive, i.e. psychotic symptoms, negative symptoms 
involving deficits in social and emotional functioning, and cognitive impairment. 
Positive and negative symptoms often follow different courses over time (Eaton et al., 
1995), respond differently to pharmacological treatment and may have different 
etiologies. Positive symptoms often respond well to treatment with antipsychotic 
medication, are associated with good premorbid adjustment, higher educational level 
and later age at onset. Negative symptoms are more difficult to treat and often persist 
despite treatment, are associated with poor premorbid adjustment, lower educational 
level, and more pronounced cognitive impairment (Andreasen et al., 1990). It is often  
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the negative and cognitive aspects of the disorder presenting a challenge for patients to 
manage everyday tasks (Green, 1996). 
 
The global lifetime prevalence of schizophrenia has been reported to be approximately 
0.4-0.9%, with newer revisions tending to show lower estimates (McGrath et al., 2008; 
Perälä et al., 2007; Saha et al., 2005). Heredity estimates reach 80-85% (Cardno and 
Gottesman, 2000). No difference in prevalence between developed and developing 
countries (World Health Organization, 1979), nor between men and women (Murray 
and Os, 1998) exists.   
 
Patients with schizophrenia suffer from excess morbidity and die 12-15 years earlier 
than the general population (Crump et al., 2013a). A recent review assessed suicide 
rates to 5%, although estimates as high as 20% has also been reported (Hor and Taylor, 
2010; Osborn et al., 2008). The main reason for the increased mortality is however the 
presence of concomitant somatic illness, mainly cardiovascular (Crump et al., 2013b; 
Schoepf et al., 2014). A vast need for healthcare recourses, in combination with the fact 
that a large proportion of patients will face social exclusion and unemployment 
throughout their lives, produces substantial societal costs, both in Sweden and 
worldwide, seldom fully appreciated by decision makers (Ekman et al., 2013; Knapp et 
al., 2004). These devastating consequences make schizophrenia rank among the top ten 
causes of disability-adjusted life years (DALY's) in the world (Lopez and Murray, 
1998; Rössler and Salize, 2005). 
 
The onset of schizophrenia generally occurs during late adolescence or early adult life 
and patients typically come to the attention of mental health care during their first 
psychotic episode. The psychosis is however often preceded by a period of prodromal 
symptoms that can be present for years before the psychotic outbreak (Yung and 
McGorry, 1996). The presence of subtle symptoms already during the first years of life 
in some patients who later develop schizophrenia is indicative of schizophrenia being a 
neurodevelopmental disorder (Marenco and Weinberger, 2000; Weinberger, 1988).  
 
Several studies claim that there is a continuum of schizophrenia-like symptoms in the 
population, ranging from sub-clinical personality traits, through the schizotypal 
personality disorders and with manifest schizophrenia and psychotic bipolar disorder at 
the far end of the spectrum (See Siever and Davis, 2004 for review). Milder phenotypes  
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of the continuum can be present as sub-clinical traits in unaffected relatives of patients 
with schizophrenia and offers a valuable opportunity to study the pathophysiology of 
these particular traits, unbiased by the many factors, including medication, a chronic 
schizophrenia diagnosis presents. 
 
Two main theories of the pathophysiology of schizophrenia are widely acknowledged. 
The dopamine hypothesis, first formulated in 1966 and based on the pioneering work of 
Arvid Carlsson (Carlsson and Lindqvist, 1963; Van Rossum, 1966), claims that 
dopaminergic hyperactivity is responsible for the symptoms observed in schizophrenia. 
The initial dopamine hypothesis was focusing on increased dopaminergic transmission 
in subcortical regions but could not explain the presence of negative symptoms and 
cognitive dysfunctions in schizophrenia. During the last decades of the 20th century it 
was hypothesized that altered functions of the dopamine system in the prefrontal cortex 
(PFC) could account for the negative and cognitive domains in schizophrenia (Knable 
and Weinberger, 1997). It became increasingly apparent that dopamine transmission 
through dopamine 1 (D1) receptors was crucial for normal prefrontal functions 
(Goldman-Rakic et al., 2000), and  the dopamine hypothesis was expanded to include a 
prefrontal dopaminergic hypofunction, in addition to the increased subcortical 
transmission (Davis et al., 1991). The glutamate deficiency theory was born with the 
report by (Kim et al., 1980) of low cerebrospinal fluid (CSF) levels of glutamate in 
patients with schizophrenia and in similarity to the dopamine hypothesis it was backed 
up by a range of pharmacological evidence involving the glutamatergic N-methyl D-
aspartate (NMDA) receptor. For example, synthetic NMDA receptor antagonists like 
ketamine produce psychotic symptoms often indistinguishable from schizophrenia in 
healthy individuals (Allen et al., 1978), and worsen symptoms in patients with 
schizophrenia (Malhotra et al., 1997). Likely, these theories mirror some of the 
extremely complex pathological processes leading to the development of 
schizophrenia.  
 
In addition, and congruent with these well-established hypothesis, a great number of 
risk factors of both environmental and genetic origin have been associated with the 
development of schizophrenia, and likely the disorder is a result of the combination of 
the two.  
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1.2 BIPOLAR DISORDER 
Previously known as manic-depressive disorder, bipolar disorder, as the name implies, 
is a disorder of affective fluctuations and is increasingly being viewed as a continuum 
of mood symptoms. Symptoms can range from mild depression and brief hypomania, 
as present in cyclothymia, through bipolar disorder II, characterized by depressive and 
hypomanic episodes, to the most severe and incapacitating bipolar disorder I. Bipolar 
disorder I is characterized by severe manic and depressive episodes, and may in 
extreme cases present with predominantly mania and psychosis (Müller-Oerlinghausen 
et al., 2002). About 50% of patients experience psychotic symptoms, frequently being 
grandiose delusions (Dunayevich and Keck, 2000). The psychotic states may however 
involve all types of psychosis, including mood-incongruent, bizarre and first rank 
symptoms as well as catatonia and formal thought disorder, symptoms previously 
believed to be specific to schizophrenia (Pope and Lipinski, 1978). The psychotic 
symptoms, also common in bipolar disorder II (Mazzarini et al., 2010), may appear 
during manic as well as during depressive episodes. Patients can also experience mixed 
episodes where symptoms of mania and depression are present simultaneously. Patients 
typically spend a larger proportion of their life in depressive, rather than hypomanic or 
manic states.  (Phillips and Kupfer, 2013). Between the manic and depressive episodes, 
most patients experience a neutral mood, referred to as the euthymic state. People with 
bipolar disorder also suffer from cognitive impairment, in particular deficits in 
executive function, sustained attention, and verbal memory and learning are observed. 
Few studies have investigated premorbid cognitive function in patients who later 
develop bipolar disorder. The cognitive impairment is evident from the onset of the 
disorder, present also during euthymic states and likely cognition deteriorates over time 
(Ferrier et al., 1999; Martínez-Arán et al., 2004; Quraishi and Frangou, 2002; Robinson 
et al., 2006). Impairment in investigated cognitive domains often worsen during mood 
episodes, in particular manic, and has been shown to be associated with duration of 
illness, number of episodes, and number of hospital admissions (Cavanagh, 2002; 
Clark, 2002; Denicoff et al., 1999; Fossati et al., 2004).  
 
The lifetime prevalence has been estimated to 0.6% for bipolar disorder I and 0.4% for 
bipolar disorder II. The age of onset is usually in the late adolescent, early adult period 
with a mean age of onset at 18 and 20 years for bipolar disorder I and II,  
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respectively (Merikangas et al., 2011). Gender, race and ethnicity does not impact the 
prevalence rates (Merikangas et al., 2011; Weissman et al., 2014). As opposed to the 
more severe bipolar disorder I with severe manic and depressive states critically 
impairing normal function, the other diagnostic subtypes have tended to be under-, or 
misdiagnosed. It has been shown that approximately 30% of patients receiving mood-
stabilizing treatment do not have a bipolar diagnosis (Angst et al., 2010; Phillips and 
Kupfer, 2013).  
 
Bipolar disorder heritability rates are assessed to 60-85% (Smoller and Finn, 2003). 
Suicide is a common cause of death, with rates for completed suicide being 15 for 
males and 22 for females and the general mortality rates in patients with bipolar 
disorder are 2.5 times higher than in the general population (Osby et al., 2001). Despite 
the hardships of a serious mental illness, patients with bipolar disorder are often 
overrepresented in creative professions (Kyaga et al., 2011; Redfield Jamison and 
Freeman, 1993).  
 
In contrast to schizophrenia, only a few environmental risk factors for bipolar disorder 
have been identified. In a study investigating a number of known schizophrenia risk 
factors in a bipolar cohort, the only factor shown to increase the risk of attaining the 
disorder was early parental loss, in particular maternal (Mortensen et al., 2003). 
Moreover, low social support is also associated with several features of the disorder, 
including greater risk for relapse and a worse course of the disorder, and stressful life 
events are known triggers of both the onset of bipolar disorder and subsequent affective 
episodes (Alloy et al., 2005).  
 
There is evidence for a dopaminergic component also in mania, presented by the fact 
that dopamine-releasing drugs can induce also symptoms of mania and that dopamine-
blocking antipsychotics are effective in treating mania. In similarity with the dopamine 
hypothesis of schizophrenia, mesolimbic dopamine hyperactivity is likely involved in 
the psychotic states in bipolar disorder (Cousins et al., 2009). Also glutamate 
dysregulation is likely contributing to symptoms of bipolar disorder, and both lithium 
and a number of antidepressants have been shown to modify glutamatergic signaling 
through NMDA receptors (Rapoport et al., 2009). 
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1.3 SIMILARITIES AND DIFFERENCES BETWEEN 
SCHIZOPHRENIA AND BIPOLAR DISORDER  
Even if diagnostic systems offer easily distinguishable diagnostic criteria for 
schizophrenia and bipolar disorder, the distinction is not as obvious in the clinical 
reality, as schizophrenia and bipolar disorder share many features. Both strike at the 
sensitive period of adolescence or early adulthood, and present a lifelong and episodic 
disease course where both onset and subsequent episodes are often triggered by adverse 
life events (Alloy et al., 2005; Ventura et al., 1989). Psychotic symptoms in bipolar 
disorder might be hard to distinguish from schizophrenia and both mania and psychosis 
respond to dopamine blockade, indicating that dopaminergic hyperactivity is also 
underlying manic symptoms (Cousins et al., 2009). Conversely patients with 
schizophrenia often present with depression, specifically during the prodromal phase 
and first episode (Häfner et al., 1999) and it has been suggested that negative symptoms 
are a distinguishable entity also in depression (Winograd-Gurvich et al., 2006).  
 
Parts of the genetic basis of schizophrenia are shared with bipolar disorder. In a large 
twin study, it was assessed that the monozygotic (MZ) co-twins of probands with 
schizophrenia had increased risks of schizophrenia (40.8%), as well as mania (8.2%) 
while the MZ co-twins of manic probands had increased risk of mania (36.4%) as well 
as schizophrenia (13.6%) (Cardno et al., 2002). Also, molecular genetic studies report a 
substantial overlap in susceptibility genes to both of the disorders (Lichtenstein et al., 
2009; Purcell et al., 2009). 
 
There is however a number of fundamental differences pointing to the fact that even 
though the disorders may share certain neurophysiological qualities they are not merely 
disorders on the same continuous scale differing only in severity. As already 
mentioned, bipolar disorder is not associated with the array of environmental risk 
factors that haunts schizophrenia (Mortensen et al., 2003). In contrast to patients with 
schizophrenia who often display a long period of reduced premorbid functioning before 
the psychotic break, patients with bipolar disorder are often high achievers prior to 
disease onset (Goldberg, 1999). The low premorbid functioning in schizophrenia is 
often reflected in structural and functional brain abnormalities observed in high-risk 
individuals who later develop schizophrenia, and becomes progressively worse during  
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the course of the disorder (Pantelis et al., 2003, 2005; Wright et al., 2000). The most 
commonly observed structural anomalies in schizophrenia are reduced cerebral volume, 
reduced gray matter in the medial temporal lobe, including amygdala and hippocampus, 
and enlarged ventricles (Honea et al., 2005; Wright et al., 2000). The research field is 
more ambiguous when it comes to structural abnormalities in bipolar disorder, and both 
positive and negative reports and meta-analyses have been published (McDonald et al., 
2004; Selvaraj et al., 2012). This difference might also be reflected in the difference in 
cognitive impairment between the two disorders, where studies consistently report 
milder cognitive deficits in patients with bipolar disorder compared to schizophrenia. 
The only cognitive domains frequently reported to be impaired in bipolar disorder are 
deficits in verbal memory and executive function (Goldberg et al., 1993; Martínez-Arán 
et al., 2004). Having the shared genetic basis of psychosis and the differences in 
cognition and brain structures in mind, it has been suggested that schizophrenia arises 
due to a genetic vulnerability in combination with neurodevelopmental insults, while 
bipolar disorder does not (Murray et al., 2004). 
 
 
1.4 THE KYNURENINE PATHWAY 
Kynurenic acid, as the name implies, was discovered in canine urine in 1853 by Justus 
von Liebig (Liebig, 1853). However, it was not recognized as a metabolite of the 
essential amino acid tryptophan until 50 years later (Ellinger, 1904). The other 
metabolites in what was later termed the kynurenine pathway were subsequently 
identified, and it was found that the kynurenine pathway accounts for ~95% of the 
human tryptophan metabolism (Wolf, 1974). 
 
The entry of tryptophan into the kynurenine pathway is guarded by the two rate-
limiting enzymes indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase 
(TDO; Figure 1). 
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Figure 1. The kynurenine pathway 
 
Following hydroxylation of tryptophan by IDO or TDO to form N-formylkynurenine, it 
is further metabolized to kynurenine by the action of kynurenine formamidase (Mehler 
and Knox, 1950). Kynurenine, the pivotal compound of the pathway, can then follow 
three separate paths; i) It can be metabolized to form KYNA through the actions of one 
of the kynurenine aminotransferase (KAT) enzymes (KAT 1, KAT 2, KAT 3 or 
mitAAT). ii) Form anthranilic acid through the action of kynureninase (KYNU). iii) 
Form 3-hydroxykynurenine (3-HK), through the action of kynurenine 3-
monooxygenase (KMO; Moroni, 1999). 
 
KYNA is an end-metabolite, while anthranilic acid and 3-HK are further metabolized 
to 3-hydroxyanthranilic acid (3-HAA) by a non-specific oxidation or KYNU 
respectively. 3-HAA is then converted to 2-amino-3-carboxymuconic acid 
semialdehyde by 3-hydroxyanthranilate 3,4-dioxygenase and then further converted to 
quinolinic acid (QUIN) by a nonenzymatic process. Finally, QUIN is metabolized by 
quinolinate phosphoribosyltransferase (QPRT) and incorporated into nicotinamide 
adenine dinucleotide (NAD+; Guidetti et al., 1995; Guillemin et al., 2001a, 2005a, 
2007; Moroni, 1999; Stone, 1993). 
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Synthesis of the two principal metabolites of the kynurenine pathway, KYNA and 
QUIN, are spatially separated in the brain. KAT enzymes are preferentially expressed 
in astrocytes, which do not express KMO, thereby making astrocytes the main KYNA 
producing cell type in the brain (Guidetti et al., 2007; Guillemin et al., 2001a). KMO 
and KYNU, on the other hand, are primarily expressed by microglia and macrophages, 
which express only minute amounts of KAT, and QUIN is, therefore, mainly produced 
in these cells (Lehrmann et al., 2001). 
 
KYNA does not easily pass the blood brain barrier (BBB; Fukui et al., 1991), but is 
removed from the  central nervous system (CNS) by a probenecid sensitive transport 
mechanism (Moroni et al., 1988) and further eliminated by urinary excretion (Turski 
and Schwarcz, 1988). It is also suggested that astrocytes can take up and eliminate 
QUIN by means of the enzyme QPRT that is highly expressed in these cells (Guillemin 
et al., 2001a). In addition to the main metabolites KYNA and QUIN, the metabolites 3-
HAA and 3-HK also have neuroactive properties. 
 
 
1.4.1 Neurochemical properties of kynurenines 
KYNA is the only known endogenous metabolite to antagonize N-methyl D-aspartate 
(NMDA) receptors. At low micromolar concentrations (IC50 ≈ 8-15 µM) it 
competitively blocks the strychnine-insensitive glycine site of the NMDA receptor 
(Birch et al., 1988; Kessler et al., 1989; Parsons et al., 1997). At higher concentrations 
(IC50 ≈ 0.2-0.5 mM) it antagonizes the glutamate recognition site of the NMDA 
receptor. In even higher concentrations in the millimolar range, it also competitively 
antagonizes glutamatergic receptors of the AMPA and kainate types (Kessler et al., 
1989), however the physiological relevance of this is not clear. At low concentrations 
(IC50 ≈ 7 µM), KYNA non-competitively antagonizes the α7 nicotinic acetylcholine 
(α7nACh) receptor (Hilmas et al., 2001). Recently KYNA was also proposed as an 
endogenous agonist of the GPR35 receptor (Wang et al., 2006), and the finding that 
KYNA is a ligand of the aryl hydrocarbon receptor (AhR; DiNatale et al., 2010) has 
spurred research of the actions of KYNA through the AhR in the field of inflammatory 
research. In addition to its receptor-mediated actions, KYNA might be a free radical 
scavenger and an endogenous antioxidant (Lugo-Huitrón et al., 2011). 
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As opposed to KYNA, QUIN is an excitatory neurotoxin, mediating its effects through 
its agonistic actions on the NMDA receptor (IC50 ≈180µM; Stone, 1993), and has also 
been described as a free radical generator (Rios and Santamaria, 1991), a feature it 
shares with 3-HK (Eastman and Guilarte, 1989). Both 3-HK and 3-HAA also generate 
superoxide and hydrogen peroxide (Goldstein et al., 2000). Moreover, QUIN was 
recently shown to stimulate the release of glutamate from neurons, inhibit glutamate 
uptake into astrocytes and inhibit astrocytic glutamine synthetase (Tavares et al., 2000, 
2002; Ting et al., 2009), and its actions are further investigated in a number of different 
contexts (see Guillemin, 2012 for review). 
 
 
1.4.2 Regulation of the kynurenine pathway 
The first point for regulation of the kynurenine pathway is the initial and rate-limiting 
step involving IDO and TDO. These two enzymes have different cellular distribution 
and respond to different stimuli (Batabyal and Yeh, 2007). IDO is mainly present in 
certain immune cells, such as dendritic cells and macrophages (Moffett and 
Namboodiri, 2003), intestine, lung, placenta and brain (Stone, 1993), and it is generally 
accepted that it is activated by immune stimuli such as cytokines (King and Thomas, 
2007). TDO has long been recognized as a predominantly hepatic enzyme; however, it 
is now known to be also expressed in the CNS (Guillemin et al., 2007; Kanai et al., 
2009, 2010; Ohira et al., 2010). Hepatic TDO is chiefly regulated by levels of 
tryptophan and glucocorticoids (Stone, 1993). 
 
Since the main KYNA producing enzymes, KAT 1 and KAT 2 have Michaelis Menten 
constants (Km) in the millimolar range (Guidetti et al., 1997; Okuno et al., 1991), the 
production of KYNA is mainly governed by the availability of the immediate 
precursor, kynurenine (Schwarcz and Pellicciari, 2002). The production of KYNA is 
hereby critically dependent on the activity of IDO and TDO. This notion is supported 
by experiments where kynurenine is administered systemically to both rats and 
primates, giving rise to elevated levels of KYNA (Jauch et al., 1993; Swartz et al., 
1990; Wu et al., 1992). Glutamine and phenylalanine are also competitive substrates for 
KAT 1 and KAT 2, and therefore the intracellular concentrations of these amino acids, 
may indirectly affect the rate of KYNA formation (Chang et al., 1997). KMO, 
converting kynurenine to 3-HK has a Km≈20 µM (Bender and McCreanor, 1985) and  
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can be considered a critical enzyme also for KYNA formation, in the sense that a lower 
activity of this enzyme will accumulate kynurenine that in turn will be processed by the 
KAT enzymes. This is likely the scenario under physiological conditions, as well as in 
psychiatric disorders such as schizophrenia, where KYNA, but not 3-HK and QUIN are 
found elevated (Schwarcz et al., 1988). Increased activity of KMO has been observed 
in a mouse model of Huntington's disease, likely explaining the elevated levels of 
QUIN and 3-HK in the early stages of this disorder. 
  
A number of approaches are frequently employed to increase the brain concentration of 
KYNA in an experimental setting. Drugs inhibiting KMO will indirectly increase the 
production of KYNA through increased kynurenine availability (Russi et al., 1992; 
Speciale et al., 1996). As previously mentioned, it is also possible to administer the 
immediate precursor kynurenine, which readily passes the BBB, and can, therefore, be 
administered systemically. Administering probenecid impairs the transport of KYNA 
from the brain and thereby also increases the central concentration (Moroni et al., 
1988). 
 
 
1.4.3 Regulation of the kynurenine pathway by immunological stimuli 
The research of a link between the immune system and the kynurenine pathway has 
been around since the finding that IDO is induced by lipopolysaccharide (LPS; Yoshida 
and Hayaishi, 1978) and evidence of this connection are presently mounting. It was 
soon recognized that the relation between infection and activation of the kynurenine 
pathway is mediated by cytokines, molecules coordinating the immune response to 
infection and other inflammatory stimuli (Yoshida et al., 1981).  
 
The pro-inflammatory cytokine interferon-γ (IFN-γ) is considered the principal 
activator of IDO and thus the kynurenine pathway (See Taylor and Feng, 1991, for 
review). Other cytokines, such as tumor necrosis factor (TNF) and interleukin (IL)-1 
has however been shown to act synergistically with IFN-γ to induce IDO enzyme 
activity in vitro (Babcock and Carlin, 2000; Robinson et al., 2003), or to activate IDO 
independent of IFN-γ (Fujigaki et al., 2006; Guillemin et al., 2001b). IFN-γ has the 
capacity to induce the mRNA expression of KAT-I and KAT-II in human astrocytes in 
vitro (Guillemin et al., 2001a), but also give  rise to elevated levels of QUIN in the  
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mouse brain (Saito et al., 1991, 1992). A neurotropic influenza virus administered to 
neonatal mice, activates several enzymes of the kynurenine pathway, including both 
IDO and the QUIN branch enzymes KMO, KYNU, and HAOO, and give rise to a 
transient increase in KYNA levels (Asp et al., 2010; Holtze et al., 2008). Studies on 
macaques show elevated levels of both KYNA and QUIN in macaques infected with 
the simian immunodeficiency virus (Heyes et al., 1992a, 1998) and elevated levels of 
QUIN following infection with polio (Heyes et al., 1992b). Several studies have 
investigated the effect of the parasite Toxoplasma gondii on the kynurenine pathway. 
For example, mice infected with this parasite show induction of IDO, and elevated 
levels of kynurenine and QUIN, an effect likely mediated through IFN-γ (Fujigaki et 
al., 2002; Notarangelo et al., 2014; Silva et al., 2002). 
 
As opposed to IDO, TDO was initially not considered to be regulated by 
immunological stimuli (Heyes et al., 1998; Saito et al., 1992, 1993). Later, however, 
increased expression of TDO mRNA was observed in human placenta following 
bacterial intra-uterine infection, as well as in placental cells following LPS stimulation 
(Manuelpillai et al., 2003, 2005). Another study reported on antimicrobial and 
immunoregulatory effects of TDO in an inducible TDO expressing cell system 
(Schmidt et al., 2009). 
 
In clinical settings, it has also been observed that the kynurenine pathway is frequently 
activated during infections, as well as during inflammatory conditions of the CNS 
(Heyes et al., 1992c). Elevated levels of KYNA have been found in patients with tick 
borne encephalitis (Holtze et al., 2012a) herpes simplex virus type 1 encephalitis (Atlas 
et al., 2013), cerebral malaria, (Dobbie et al., 2000; Medana et al., 2003) and HIV-1, 
where also kynurenine and QUIN are elevated (Achim et al., 1993; Atlas et al., 2007; 
Baran et al., 2000; Heyes et al., 1991, 1998, 2001). Elevated levels of QUIN have also 
been observed in Lyme disease (Halperin and Heyes, 1992). In addition, 
immunotherapy with IFN-α has been found to activate the kynurenine pathway (Raison 
et al., 2010). 
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1.4.4 Physiological significance of the kynurenine pathway 
Since the discovery that intracerebroventricular (i.c.v) injection of QUIN causes 
seizures in mice, (Lapin, 1978), and subsequently the discovery that KYNA is 
synthesized in the brain (Moroni et al., 1988; Turski et al., 1988), the physiological 
relevance of central kynurenines have gained increased attention. Since the 
concentration of both QUIN and KYNA are found in the rodent brain in concentrations 
far below the levels needed to exert an action on the different receptors in vitro (see 
1.2.2), it has been an issue of controversy whether metabolites of the kynurenine 
pathway exert any physiological actions in the CNS.  There is however a number of 
rationalizations to the apparent mechanistic gap between observed effects on one hand 
and brain concentrations and receptor efficacy on the other hand. 
 
During the late 1990's, it became increasingly apparent that astrocytes actively 
contribute to synaptic transmission. Astrocytes tightly engulf the synapse in an 
interaction termed "the tripartite synapse" (Araque et al., 1999), where they can respond 
to released neurotransmitters by releasing factors of their own, thereby modulating the 
synaptic transmission (See Araque et al., 2014 for review). Since astrocytes are the 
prime source of KYNA the concentration at the synaptic cleft in all probability reaches 
the required levels to block NMDA and α7nACh receptors. 
 
The often-dramatic effects of experimentally administered QUIN in the CNS are, on 
the other hand, attributed to a combination of factors. Firstly, QUIN seem to lack 
efficient removal mechanisms in the CNS (Foster et al., 1984). Secondly, the 
excitotoxic actions through NMDA receptors are likely potentiated by the simultaneous 
generation of free radicals (Behan and Stone, 2002). QUIN selectively activates NR2A 
and NR2B subtypes of the NMDA receptor, predominantly present in the forebrain 
(Prado De Carvalho et al., 1996). 
 
Although the complexity of the interactions between kynurenines and neuronal circuits 
is just beginning to dawn on us, it is beyond doubt that they play a role in human 
physiology and pathology.  During the last decades, the interest in the role of the 
kynurenine pathway in a range of different medical conditions has almost exploded, 
hence opening up the arena for new insights. 
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The impact of kynurenines in neurodegenerative disorders has been studied for 
decades. KYNA has been reported elevated in Alzheimer's disease (Baran et al., 1999), 
and in amyotrophic lateral sclerosis (ALS; Iłzecka et al., 2003). However, the 
kynurenine pathway metabolite most often discussed in relation to neurological and 
neurodegenerative disorders is the NMDA receptor agonist QUIN, shown to act as a 
neurotoxin in the CNS (Schwarcz et al., 1983; Stone and Perkins, 1981). QUIN has 
been most thoroughly investigated in Huntington’s disease, where QUIN levels are 
elevated in the initial stages of the disease, especially within the most affected brain 
regions (Guidetti et al., 2004). This increase in QUIN is matched by a similar increase 
in 3-HK levels (Guidetti et al., 2004; Pearson and Reynolds, 1992), and it is likely that 
the simultaneous actions of these two compounds work in a synergistic fashion 
(Guidetti and Schwarcz, 1999). Also in Alzheimer both 3-HK and QUIN are found in 
higher concentrations, and QUIN immunoreactivity is found mainly in association with 
amyloid plaques (Bonda et al., 2010; Guillemin et al., 2005b). Pathological changes in 
Parkinson and ALS are likely also under the influence of kynurenine metabolism (Chen 
et al., 2010; Zinger et al., 2011) 
 
It is conceivable that the elevated levels of KYNA sometimes observed in patients with 
neurodegenerative disorders might be a consequence of the elevated levels of QUIN, 
where the synthesis of KYNA is increased in order to counteract the neurotoxic effects 
of centrally elevated QUIN. This assumption is supported by several studies showing 
that KYNA has neuroprotective properties, likely mediated through the antagonizing 
effect on NMDA receptors, and possibly also α7ACh receptors (Foster et al., 1984; 
Miranda et al., 1997; Sapko et al., 2006; Stone, 1993; Zwilling et al., 2011; Atlas et al., 
2013). In patients with HIV-1, serving as the most severe prototype of a viral disease, 
CNS QUIN and 3-HK are also elevated, too a much higher degree than the previously 
mentioned increase in KYNA in these patients (Heyes et al., 1990, 1991, 1992c). 
 
Not only is the kynurenine pathway activated by immunological stimuli (see 1.4.3), but 
it has also become increasingly apparent that it takes part in a number of 
immunological processes. Already during the early 1980’s it was noted that tryptophan 
degradation accompany immune activation (Pfefferkorn, 1984), and it was generally 
believed that the observed antimicrobial effect was a result of the removal of the 
essential nutrient tryptophan from the pathogen, thus inhibiting its growth. Several 
studies since have noted that IDO activation contributes to the development of  
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tolerance by inhibiting T-cell responses (Mándi and Vécsei, 2012; Mellor and Munn, 
2004). IDO has been shown to mediate tolerance to tumors (Munn and Mellor, 2007), 
preventing fetal rejection (Munn et al., 1998), and has been implicated in mediating 
protection against autoimmunity (Fallarino et al., 2009; Grohmann et al., 2003; Saxena 
et al., 2007; Yan et al., 2010). At least some of these processes are plausibly mediated 
by the metabolites downstream of IDO. Kynurenine has been described to inhibit 
natural killer (NK)-cell responses (Della Chiesa et al., 2006), and kynurenine, 3-HK 
and 3-hydroxyanthranilic acid has been shown to suppress T-cell responses (Terness et 
al., 2002).  
 
KYNA has also been shown to display immunogenic properties. For example, it 
attenuates the production of TNF-α in mononuclear cells, an effect believed to be 
mediated through its binding to the GPR-35 receptor (Wang et al., 2006), and it also 
inhibits the production of CD14+ peripheral blood monocytes (Tiszlavicz et al., 2011). 
Inhibition of TNF-α production by KYNA may be contributing to its neuroprotective 
effects (Mándi and Vécsei, 2012). 
 
As a consequence of the realization of the role the kynurenine pathway plays in 
immunological and tolerogenic processes, kynurenine pathway metabolites are now 
also being investigated in a multitude of conditions, such as inflammatory pain certain 
autoimmune disorders, and cancer. 
 
 
1.4.5 The kynurenine pathway in psychiatric disorders 
It was early recognized that tryptophan metabolism might impact psychiatric disorders. 
As early as in the 1970’s, the connection between tryptophan metabolism and 
depression was documented (Curzon and Bridges, 1970; Lapin, 1973). The focus of 
depression research however soon shifted from kynurenines to serotonin, as the use of 
serotonin reuptake inhibitors became a full-blown success story. Nonetheless, as the 
serotonin hypothesis of depression have failed to explain many of the observed features 
of the disorder as well as the slow onset of the treatment effects of serotonin reuptake 
inhibitors, interest has shifted back to kynurenines in recent years. Increased 
breakdown of tryptophan has been observed in depressed patients (Maes et al., 2000), 
as well as in patients receiving IFN-α treatment who subsequently develop depression  
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(Capuron et al., 2003). IDO activation by the immune system is a central finding in 
experimental models connected to the development of depressive-like behavior that 
temporally occurs when the sickness behavior per se is waning (Dantzer et al., 2008). It 
is however less clear how the increased activity of the kynurenine pathway can trigger 
depressive behavior, and which metabolites play a role in the pathological mechanisms. 
A plausible scenario is that a dysregulation of the pathway, favoring production of 
neurotoxic metabolites such as 3-HK and QUIN, is responsible for the symptoms and 
observed loss in hippocampal volume in depression (Müller and Schwarz, 2007; 
Sheline et al., 1996). Increased QUIN immunoreactivity and decreased astrocyte 
density is found in post mortem brains of patients with depression (Si et al., 2004; 
Steiner et al., 2011). In two recently published studies on suicide, of which 
approximately half the patients suffered from depression CSF QUIN was elevated 
while CSF KYNA was not. In one study QUIN correlated to ratings on the suicide 
intent scale (Erhardt et al., 2013) and the other study reported an association between 
low levels of KYNA and severity of depression, as well as ratings on the suicide 
assessment scale (Bay-Richter et al., 2014). These studies are indicative of an NMDA 
mediated mechanism of depressive symptoms, where lower levels of KYNA could 
augment the vulnerability of, in particular hippocampal, neurons to the neurotoxic 
effects of NMDA receptor over-activation by QUIN. This is also in line with the 
findings that NMDA receptor antagonists such as ketamine produce a rapid and long 
lasting antidepressant effect in depressed patients (Berman et al., 2000). The 
complexity of the situation is however illustrated by the finding that in patients 
receiving IFN-α treatment for chronic hepatitis or cancer, both QUIN and KYNA are 
equally elevated in the CSF (Raison et al., 2010). Depression following IFN-α 
treatment is however a specific subtype of induced depression, and this finding might 
not be representative for the entire group of patients suffering from endogenous 
depression.   
 
Findings of an abnormal tryptophan metabolism in schizophrenia date back more than 
50 years. Following a tryptophan load, patients with schizophrenia were observed to 
excrete 2.4 times the amount of tryptophan metabolites as normal controls (Benassi et 
al., 1961). The discovery of KYNA in the human brain (Moroni et al., 1988; Turski et 
al., 1988) spurred further research on the link between tryptophan metabolism and 
schizophrenia, and KYNA, was soon found in elevated concentrations in the brain and 
CSF of patients with schizophrenia  (Erhardt et al., 2001a; Schwarcz et al., 2001). The  
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metabolite in focus since the initial finding has been KYNA, and numerous studies 
confirm these findings of elevated levels of both KYNA, and more recently, its 
precursor kynurenine in the CNS of patients with schizophrenia (Erhardt et al., 2001a; 
Linderholm et al., 2012; Miller et al., 2006; Nilsson et al., 2005; Sathyasaikumar et al., 
2011; Schwarcz et al., 2001). Importantly, increased expression of TDO, but not IDO 
has also been observed in the brains of patients with schizophrenia (Miller et al., 2004, 
2006). It was confirmed that the elevated levels of KYNA in patients with 
schizophrenia was not a medication effect in a study where both medicated and drug-
naïve patients had higher levels than healthy controls (Nilsson et al., 2005). Elevated 
CSF levels of KYNA, and brain levels of kynurenine, has also been observed in bipolar 
disorder, where the highest levels were observed in the group with psychotic features 
(Miller et al., 2006; Olsson, 2010; Olsson et al., 2012a). Further supporting a role for 
KYNA specifically in psychosis, are the findings that KYNA is elevated in patients 
with HIV with psychotic symptoms (Atlas et al., 2007). Also, patients who are 
suffering anti-NMDA receptor encephalitis, a condition in which autoantibodies target 
brain NMDA receptors, frequently present with psychosis (Dalmau et al., 2011). 
 
 
1.4.6 The kynurenic acid hypothesis of schizophrenia 
Since KYNA has known neuroactive properties, being an antagonist at the glycine site 
of the NMDA receptor and of the α7nACh receptor, it was a natural step to start to 
investigate the relevance of elevated levels of this compound in experimental models. 
Synthetic NMDA receptor antagonists can produce psychotic symptoms, often 
indistinguishable from schizophrenia, in healthy people, and aggravate symptoms in 
patients with schizophrenia (Allen et al., 1978; Malhotra et al., 1997). Synthetic 
NMDA antagonist has also been shown to impact the activity of midbrain dopamine 
neurons in rats (French, 1994; French et al., 1993). 
 
In line with this, endogenous KYNA has been shown to tonically modulate firing of rat 
midbrain dopaminergic neurons, with elevated levels of KYNA leading to increased 
firing (Erhardt and Engberg, 2002; Erhardt et al., 2001b; Linderholm et al., 2007; 
Nilsson et al., 2006), and lower levels of KYNA decreasing the firing rate of dopamine 
neurons (Schwieler et al., 2006, 2008). Elevated levels of KYNA in the rat also changes 
the dopamine response to amphetamine (Olsson et al., 2009), in line with the fact that  
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patients with schizophrenia show an abnormal dopaminergic response to amphetamine 
compared to healthy controls (Abi-Dargham et al., 1998; Laruelle, 1998; Laruelle and 
Abi-Dargham, 1999). These data are indicative of an involvement of KYNA in the 
positive symptoms of schizophrenia. 
 
KYNA also bi-directionally modulates the release of glutamate both in cortical areas 
and the hippocampus (Konradsson-Geuken et al., 2010; Pocivavsek et al., 2011), as 
well as the release of cortical acetylcholine (Zmarowski et al., 2009), and cortical 
GABA (Beggiato et al., 2014). Glutamatergic and cholinergic neurotransmission is 
heavily implicated in cognitive functioning. It is well-known that patients with 
schizophrenia frequently show impairments in working memory as well as in verbal 
learning and memory, domains that are considered core features of the disease   
(Nuechterlein et al., 2004). Behavioral experimental studies confirm the involvement of 
KYNA in cognitive domains. Elevated levels of KYNA are shown to have an impairing 
effect on spatial memory and learning as well as on social interaction (Alexander et al., 
2012; Chess and Bucci, 2006; Chess et al., 2007; Pocivavsek et al., 2012; Trecartin and 
Bucci, 2011). Also, lowering the endogenous levels of KYNA enhances glutamate 
release, hippocampal plasticity and cognitive function (Potter et al., 2010). Elevated 
levels of KYNA also disrupts prepulse inhibition (PPI) in experimental animals 
(Erhardt et al., 2004). A defect in PPI, believed to reflect a deficit in sensorimotor 
gating, is also observed in patients with schizophrenia (Braff and Geyer, 1990). 
 
Altogether the kynurenic acid hypothesis of schizophrenia suggests that elevated levels 
of KYNA cause alterations in dopaminergic, glutamatergic, GABAergic and 
cholinergic neurotransmission, leading to the observed symptoms in schizophrenia. By 
incorporating actions on these neurotransmitter systems, the kynurenic acid hypothesis 
is not only in line with the dopamine hypothesis and the glutamate deficiency theory of 
schizophrenia, but rationally bring these hypotheses together under a common 
umbrella.  
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1.5 IMMUNE PROCESSES AND NEUROINFLAMMATION 
The classical inflammatory response as we know it is based on observations of the 
peripheral immune system and is initiated by cells of the innate immune system, 
reacting to pathogens or tissue damage. Activation is achieved through signaling via 
toll-like receptors (TLRs), pattern recognition receptors capable of recognizing 
pathogen-associated molecular patterns (PAMPs), leading to phagocytosis of pathogens 
or damaged tissue components by professional antigen presenting cells (APCs). 
Dendritic cells (DCs), macrophages or other APCs then present antigen in conjunction 
with MHC-II molecules expressed on their surface. Activation of TLRs is also coupled 
to an induction of a proinflammatory cascade leading to a swift release of cytokines, 
chemokines and other signaling molecules recruiting other types of inflammatory cells. 
APCs migrate to lymphatic nodes where T-cells are capable of responding to the 
antigen presentation by in turn releasing cytokines. Cytokines further drive the 
propagation of both the innate and adaptive immune responses through the proliferation 
and differentiation of several different T-cell subsets and antibody producing B-cells.  
 
The brain was for the most part of the previous century considered to be an immune 
privileged site. Although the definition of immune privilege has been floating and 
imprecise, a number of factors are generally attributed to the concept. Firstly, the brain 
parenchyma lack functional DCs and no other cell type has been observed performing 
the crucial tasks of antigen uptake, migration from CNS to lymphatic nodes and 
presentation of antigen to T-cells. This fact constitutes the cellular basis of the immune 
privilege of the CNS (Ransohoff and Brown, 2012). The second factor invoked to 
prove CNS immune privilege is a lack of adaptive immune responses following 
injection of immunogens into the brain parenchyma, whilst the same immunogen is 
capable of inducing a rapid response in the periphery.   
 
It is now acknowledged that the immune privilege of the CNS is not absolute. 
Immunological processes do occur within the CNS, in an intricate way controlling the 
environment of the brain in close contact with peripheral processes. The concept of 
neuroinflammation, born during the early 1990's, however acknowledged that CNS 
immune reactions are under rigid control since an inflammatory reaction, as we know it 
from the periphery, would have deleterious effects on neurons, and other CNS cell 
types with poor regenerating capacity. In addition to the BBB, often quoted as the sole  
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reason for the CNS immune privilege, the brain parenchyma is held in an 
immunosuppressed state by the release of only partially identified factors from both 
neurons and astrocytes (see Galea et al., 2007 for overview).  
 
In spite of the BBB, there are a number of routes for communication between the 
periphery and the central immune system. Immune activation by peripheral TLRs leads 
to central activation of immunological mechanisms, usually producing fever and 
sickness behavior (Dantzer et al., 2008). Primary afferents, such as the vagal or the 
trigeminal nerves, constitute main sensory routes from the periphery to the brain and 
are known conveyors of immune signals to the CNS (Bluthé et al., 1994; Goehler et al., 
2000). In addition, a humoral pathway, involving BBB endothelial cells as well as 
macrophage-like cells lining the circumventricular organs (CVOs), may contribute to 
the relay of immune signals from the periphery to brain. This route involves the 
activation of the NF-κB and cyclooxygenase (COX)-2 in BBB endothelial cells by 
peripheral IL-1β (Laflamme et al., 1999). It is also believed that phagocytic cells at the 
CVOs take up IL-1β from the periphery, in order to release it inside the brain where it 
can act on adjacent microglia (Konsman et al., 1999). Passage of cytokines into the 
brain at the leaky regions of the CVOs by volume diffusion has also been described 
(Vitkovic et al., 2000a). The cytokine signal is then believed to propagate by means of 
volume transmission within the brain (Agnati et al., 1995). The relative importance of a 
humoral route of immune signaling from periphery to brain has however been 
questioned (Dantzer et al., 2000), as has the presence of a saturable active transport 
system for cytokines such as IL-1. Such a system has been described (Banks et al., 
1995, 1991, 2001), but the molecular identity of these transporters remain evasive, and 
it is not known if they do contribute to physiological or pathological processes. 
 
Immunological reactions in the brain parenchyma are orchestrated by cells specific to 
the CNS, with mainly innate immune processes taking place. Microglia, a cell type of 
myeloid origin, often referred to as the resident macrophages of the brain, are 
considered to be the primary cell of the innate immune system in the CNS. They are 
normally present in what is referred to as a resting, or quiescent state, in which they 
nevertheless are highly active, constantly scanning their microenvironment for signs of 
infection or tissue damage (Nimmerjahn et al., 2005). Upon activation, microglia attain 
a more macrophage-like morphology, go into a proliferatory state, become motile, and 
capable of phagocytosis (Glezer et al., 2007). Activation of microglial immune  
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processes is also achieved through activation of TLRs. In the CNS, TLRs are also 
expressed by astrocytes and to some extent also by neurons (Dong and Benveniste, 
2001; Falsig et al., 2008) and the interplay between these three cell-types is crucial for 
an efficient regulation of immune processes within the brain parenchyma. The 
complexity of the interactions between the several players in the multipartite synapse is 
still under intense investigation, but glial cells are increasingly being viewed as 
essential elements in neuronal, as well as immunological signaling (Halassa et al., 
2007; Tremblay et al., 2011; Xanthos and Sandkühler, 2014) 
 
Today the term ‘neuroinflammation’ is as loosely defined as its predecessor ‘immune 
privilege’ once was.  The term is often applied to the release of cytokines within the 
brain, and in connection with diseases known to hold an inflammatory component, 
however it is increasingly apparent that what we call neuroinflammation is not 
necessarily a pathological process. Several individual cytokines are believed to be 
constitutively expressed in particular brain regions. IL-1β, a pleiotropic cytokine with 
mainly pro-inflammatory actions, has been found to contribute to long-term 
potentiation (LTP) in rats (Schneider et al., 1998), both in vivo and in vitro, and 
disrupted IL-1β signaling leads to memory deficits in rodents. Interestingly mice with 
no functional IL-1 receptor or infusion of IL-1 receptor antagonist (IL-1Ra; Avital et 
al., 2003; Yirmiya et al., 2002) show the same type of hippocampal-dependent memory 
deficits as transgenic animals overexpressing IL-1β (Hein et al., 2011), possibly 
indicating a U-shaped optimum for physiological IL-1β levels in the CNS.  IL-1β, 
production is under tight regulation, and the final step for acquiring a functional IL-1β 
molecule is the proteolytic cleavage of pro-IL-1β into mature IL-1β. This process has 
been solely attributed to caspase-1, a member of a family of cysteine proteases mainly 
involved in the regulation of apoptosis (Thornberry, 1998). Recently however a role for 
caspase-8 in the regulation and cleavage of IL-1β has been revealed (Gringhuis et al., 
2012; Maelfait et al., 2008). Caspase-8, primarily known for its actions as an initiator of 
the death receptor-induced extrinsic pathway to apoptosis (Dupaul-Chicoine and Saleh, 
2012), has now been ascribed a number of new roles, several of which are in an 
immune-related context (Burguillos et al., 2011; Oberst and Green, 2011).  
 
Also, TNF-α has been shown to be crucial for synaptic scaling in the normal brain 
(Stellwagen and Malenka, 2006), but can contribute to neuronal cell death if 
dysregulated (Allan et al., 2005; Hermann et al., 2001). These findings suggest that the  
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term ‘immune signaling' might be a more suitable expression than ‘neuroinflammation,' 
for observations of individual cytokines in the CNS, both in health and disease. Along 
this background, it was recently proposed that inflammatory reactions occur in the CNS 
in response to altered neuronal activity (Xanthos and Sandkühler, 2014), an idea that is 
in line with the many neuromodulatory actions of cytokines in the CNS (see Vitkovic et 
al., 2000b for review). 
 
 
1.5.1 Immune system involvement in psychotic disorders 
The idea that psychotic disorders are affected by immunological factors is not new. 
Over a century ago researchers made the connection between fever and ‘madness', and 
in 1927 Julius Wagner-Jauregg was awarded the Nobel Prize for his pioneering work 
on pyrotherapy (artificial fever) in mental patients. Lately, the interest in an 
immunological contribution to psychotic disorders has reemerged, to a large extent due 
to a paradigm shift in how we view the immune system of the brain (see Müller, 2014; 
Watkins et al., 2014 for reviews). 
 
Epidemiological evidence has traditionally been the strongest link to an immunological 
component in schizophrenia. Several of the confirmed risk factors for schizophrenia, 
including winter birth (Davies et al., 2003), urban living (McGrath et al., 2004), 
maternal infection during pregnancy (Brown and Derkits, 2010), and infection during 
early childhood (Dalman et al., 2008; Khandaker et al., 2012) involve an immune 
component, directly or indirectly. Early life exposure to immune activation is known to 
alter brain function later in life. In models of maternal immune activation (MIA), 
cytokine profiles in the brain differ in an age and region-specific manner (Garay et al., 
2013). Basal neurotransmission is also altered following MIA (Winter et al., 2009) and 
administration of IL-1β to mice at birth changes the dopamine content of hypothalamus 
later in life (Kabiersch et al., 1998). Early immune activation is also capable of 
changing a number of behavioral parameters associated with psychotic morbidity, 
including deficits in PPI (Asp et al., 2010; Bitanihirwe et al., 2010; Boksa, 2010). 
 
Epidemiological and experimental data are also supported by clinical findings of 
elevated levels of cytokines in patients with psychotic disorders. Numerous studies 
have over the years reported variable and often contradicting findings. In contrast to the  
Magdalena Kegel 
 31 
 
abundance of studies measuring peripheral levels of cytokines in psychotic disorders, 
reports on brain or CSF levels of cytokines are sparse and sample sizes generally small. 
Although peripheral measurements of cytokines might indicate that dysregulation of 
immune signaling in psychotic disorders is not confined to the CNS, studies of 
peripheral immune signaling are not very informative about the potential pathological 
processes in the brain. Brain immune events are, as previously described, radically 
different and relatively isolated from their peripheral counterpart, and several authors 
point out the fact that there is a noteworthy lack of correlation between levels of 
peripheral and central cytokines (de Jager et al., 2009; Lindqvist et al., 2009; Schwieler 
et al., 2014). Early studies of central levels of cytokines suffered from a number of 
serious methodological limitations, specifically in regard to inappropriate control 
groups and insensitive assays. The results from early studies are, therefore, 
contradicting and provide little value to the research of brain cytokines today. More 
recently, elevated levels of CSF IL-1β in first episode patients with schizophrenia has 
however been observed in studies from our laboratory (Söderlund et al., 2009) and 
chronic patients with schizophrenia were reported to have elevated CSF levels of IL-6 
(Schwieler et al., 2014). Two more recent studies however also reported elevated CSF 
IL-6 levels in patients with schizophrenia compared to healthy controls (Garver et al., 
2003; Sasayama et al., 2013). In a recent meta-analysis of cytokine alterations in 
schizophrenia including seven studies of CSF cytokines the only difference in CSF 
cytokine levels observed was decreased levels of IL-1β in patients compared to controls 
(Miller et al., 2011), however the author points out that the result should be cautiously 
interpreted in the light of the small number of patients included. A factor to consider in 
interpretation of these studies is the disease status of included patients. It has been 
suggested that cytokine profiles in CSF of first episode patients or in acute 
exacerbations of psychotic symptoms will differ from stable chronic states. The acute 
psychotic states would hence be associated with a more pro-inflammatory profile while 
anti-inflammatory mediators take the upper hand during resolution of psychosis (Miller 
et al., 2011). Post-mortem investigations of brain mRNA and protein expression of 
cytokines in schizophrenia constitutes a useful complement to the CSF studies, 
corroborating the findings of inflammatory signaling in the brain of patients with 
schizophrenia. Hence, IL-1Ra mRNA was found to be decreased in PFC of patients 
with schizophrenia (Toyooka et al., 2003) while TNF-α and TNF receptor 1 mRNA 
was increased (Dean et al., 2013; Paterson et al., 2006). In line with the CSF studies, 
IL-6 and IL-8 mRNA was also observed to be increased in the PFC of patients with  
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schizophrenia (Fillman et al., 2013). In this study, the elevation of IL-1β did not reach 
significance but mRNA expression of IL-1β was linked to density of MHC-II 
expressing cells in schizophrenia but not in controls (Fillman et al., 2013). In another 
recent report both protein and mRNA levels of IL-1β and TNF-α were elevated in the 
PFC of patients with schizophrenia (Rao et al., 2013).  
 
The idea that also the pathology of bipolar disorder might be under the influence of 
immunological factors is of a more recent date, and thus, the reports of central levels of 
cytokines are limited to one CSF study and one post-mortem study. Elevated levels of 
IL-1β was hence observed in the CSF of patients with bipolar disorder, with the highest 
levels observed in patients with a lifetime history of psychosis (Söderlund et al., 2011). 
Increased trans-membrane TNF-α mRNA was observed in the PFC of patients with 
bipolar disorder, however no information of the presence of psychosis in this cohort 
was provided (Dean et al., 2013). 
 
In summary, in spite of the frequently contradictory clinical findings, evidence of an 
immunological component in psychotic disorders is converging. 
 
 
1.6 GENETIC ASPECTS OF PSYCHOTIC DISORDERS 
In spite of the high heredity estimates for schizophrenia and bipolar disorder and 
decades of search for genes connected to the pathology of these disorders, no 
convincing gene candidates have emerged. The number of suggested risk genes is 
however constantly growing, even more so in the era of genome wide association 
studies (GWAS). Most of the identified candidates over the years have failed to stand 
replications and lack support by functional experimental studies. A number of critical 
factors hamper the search for genes in psychotic disorders. The frequently invoked 
polygenic background of psychotic disorders cannot alone explain the lack of success 
in the search of culprit genes. Adding evidence of strong gene-interaction effects on the 
development of these disorders and hypotheses that different subtypes of schizophrenia 
and bipolar disorder are under the influence of specific genes, presents a multi-layered 
complexity providing a worst-possible scenario for the search of genes related to the 
pathophysiology of psychotic disorders. Even though genes identified in GWAS 
screenings provide entirely new areas in which to focus our interest, such as the many  
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hits in the MHC region (Jia et al., 2012; de Jong et al., 2012),  a more fruitful approach 
to understanding the genetics behind these complex disorders might be to dissect the 
array of symptoms clustered together as “schizophrenia” or “bipolar disorder” into 
more manageable specific phenotypes. While these clusters based on DSM diagnoses 
are undoubtedly clinically and administratively useful they have proved to hold little 
value in the search for heritable factors crucial for the development of psychotic 
disorders (Weinberger, 1999). Hence the endophenotype concept in psychiatry states 
that there are measurable components connecting the disease and the distal genotype 
and that these components can aid the studies of complex disorders (Gottesman and 
Gould, 2003). Employing this approach, biological markers that can objectively be 
measured, presents ideal candidates. A number of phenotypes are under investigation in 
this context, such as deficits in sensorimotor gating (Braff et al., 2001), eye tracking 
dysfunctions (Calkins et al., 2008) as well as neurocognitive deficits (Burdick et al., 
2006; Cornblatt and Malhotra, 2001; Glahn et al., 2003). Also KYNA, a compound 
readily quantitated in the CSF and elevated in patients with schizophrenia and bipolar 
disorder can be considered an aspirant. This radically different way of investigating 
genetic foundations might, therefore, manage a task that traditional genetic approaches 
have failed to do. 
 
Twin studies have provided an invaluable contribution in determining the heredity of 
specific psychotic disorders (Kendler, 1983), as well as in establish the extent of 
overlap in the genetics between closely related disorders such as schizophrenia, 
schizoaffective disorder and bipolar disorder (Cardno et al., 2002). Twin studies 
however continue to play an essential role in identifying new phenotypes and their 
covariates within diagnostic syndromes, defining their boundaries as well as extending 
the phenotype concept to include potential biological markers (Cardno and Gottesman, 
2000).
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2 AIMS  
The overall aim of this thesis was to further explore the role of kynurenine pathway 
metabolites in the pathology of the main psychotic disorders schizophrenia and bipolar 
disorder, with a specific focus on the influence of cytokine signaling on the kynurenine 
pathway. 
 
The specific aims are: 
 
1. To investigate potential associations between CSF levels of KYNA, HVA and 
lifetime history of psychosis in patients with bipolar disorder.  
 
2. To investigate the genetic variability underlying CSF levels of KYNA in 
patients with bipolar disorder 
 
3. To map molecular signaling pathways mediating the genetic influence on CSF 
levels of KYNA 
 
4. To investigate if IL-1β alone can induce the kynurenine pathway in human 
astrocytes 
 
5. To explore potential associations between KYNA, IL-1β and set-shifting 
performance in patients with bipolar disorder.  
 
6. To investigate the levels of QUIN in the CSF of patients with chronic 
schizophrenia, and relate these levels to the levels of CSF KYNA from the same 
patients. 
 
7. To examine the possibilities of using ex vivo dermal fibroblasts as a model 
system for studies of the kynurenine pathway. 
 
8. To investigate CSF levels of tryptophan, KYNA, QUIN, HVA, 5-HIAA, IL-6, 
IL-8 and TNF-α in twins with severe psychiatric disorders, and to relate the 
levels of these metabolites to psychopathology measures.  
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3 MATERIALS AND METHODS 
3.1 ETHICS 
All studies involving human subjects were performed in compliance with the 
Declaration of Helsinki for experiments involving human subjects. Patients received 
verbal as well as written information and provided an oral and written consent to 
participate in the study. All studies were approved by the ethical review boards of 
Karolinska Institutet (paper I, II and IV), or Linköping University and the Swedish 
Medical Products Agency (paper II). 
 
 
3.2 CELL CULTURE STUDIES 
3.2.1 Cytokines and antibodies 
For paper I, human recombinant IL-1β (PHC0815) and IFN-γ (PHC4031) were 
purchased from Invitrogen (GIBCO®). Antibodies against IDO1 (ab55305), TDO2 (ab 
84926), Iba1 (ab5076), Nestin (ab6142) and S100B (ab52642) were purchased from 
Abcam (Cambridge, UK), GFAP (Z0334) from DAKO (Copenhagen, Denmark), NeuN 
(MAB377), from Chemicon (Millipore/Chemicon Billerica, Massachusetts, USA), 
Vimentin (180052) from Zymed (Invitrogen) and β-actin (A5441) from Sigma-Aldrich. 
Secondary antibodies for Western Blots were IR Dye 800 CW goat anti-mouse IgG 
(926-322, 1:10000) and IR Dye 680 CW goat anti-rabbit IgG (92632221, 1:10000) for 
use with the Odyssey system (LI-COR Biosciences, Linkoln, Nebraska, USA) or Horse 
Radish Peroxidase coupled antibodies (7076 and 7074, 1:75000) from Cell Signaling 
Technology (Danvers, Massachusetts, USA). For immunofluorescent detection Alexa-
Fluor conjugated secondary antibodies (1:300, A11029, A11032, A11034, A110379) 
from Invitrogen, were used. For paper II, TNF-α and IFN-γ 200 were purchased from 
PeproTech, London, U.K.  
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3.2.2 Fibroblast Cultures 
To establish fibroblast cultures, a cutaneous biopsy was taken from the arm of seven 
consenting volunteers recruited at Karolinska University Hospital Huddinge. Biopsies 
were minced and placed in 35 mm dishes (Corning Incorporated, Corning NY, USA) 
under a sterile glass coverslip and cultured in DMEM Glutamax, 10 mM HEPES, 1X 
MEM amino acids, 1X sodium pyruvate supplemented with 100 U/ml penicillin, 100 
µg/ml streptomycin, 15% fetal calf serum (all from Invitrogen, Paisley, UK), in a 
humidified 37°C, 5% CO2 incubator. After 2 passages, cells were seeded into 6-well 
plates (Corning Inc.). At confluence, cytokine stimulation was performed during 48 
hours using human recombinant TNF-α 100 U/ml and/or IFN-γ 200 U/ml (PeproTech, 
London, U.K.) in serum-free media, otherwise as above. Experiments were ended by 
removal and freezing of the supernatants and addition of lysis buffer to the cell 
monolayer for RNA extraction. 
 
 
3.2.3 Human Astrocyte Culture 
Human embryonic primary cortical astrocytes were purchased from ScienCell™ 
Research Laboratories (Carlsbad, CA, USA) and cultured according to manufacturers 
recommendations with some modifications. Briefly, cells were cultured in Poly-L-
lysine (P4707;Sigma) coated cell culture flasks in astrocyte media, supplemented with 
2% fetal bovine serum and a mix of growth factors comprising a final concentration of 
BSA (10 µg/ml), insulin 5µg/ml, FGF-2 (2ng/ml), IGF-I (2ng/ml), hydrocortisone 
(1µg/ml) and progesterone (20ng/ml) and containing penicillin/streptomycine (1%; 
ScienCell™). Cells were kept in 37°C in a humidified atmosphere in a 5% CO2 – 95% 
air mixture. All experiments were performed on cells in passage 4. Cells were serum 
starved (0.02% FBS and 0.01 % growth supplement mix) for 24 hours prior to 
experiments and were then stimulated with IL-1β (10 ng/ml) for 1, 3 and 24 hours for 
gene expression analysis and 24 and 48 hours for protein expression analysis. It is well 
established that IFN-γ drives IDO expression and thus IFN-γ (200ng/ml) was included 
as a positive control. All experiments were performed in triplicates and repeated twice.  
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3.2.4 RNA extraction and reverse transcription  
Following stimulation of cells in paper I, total RNA was extracted using Trizol® 
Reagent (Invitrogen) according to the manufacturer's protocol. The amount and purity 
of total RNA was measured using a NanoDrop® 1000 spectrophotometer (NanoDrop 
Technologies, Inc. Wilmington, USA). Complementary DNA was synthesized using 
TaqMan® Reverse Transcription Reagents (Applied Biosystems, Foster City, CA, 
USA) in a thermal cycler (Icycler, Bio-Rad Laboratories, Inc., Hercules, CA, USA) 
using the following program: 10 min at 25°C, 30 min at 48°C, 5 min at 95°C. Negative 
transcription controls were run, with no added reverse transcriptase to control for the 
presence of genomic DNA in subsequent real time PCR analyses. In paper III total 
RNA was extracted from the cells using the RNeasy Mini kit (Qiagen, GmbH, Hilden, 
Germany). The amount and purity of the RNA was assessed by spectrophotometry 
using a Nanodrop ND-1000. Total RNA (250 ng) was subsequently treated with 1 unit 
of amplification grade DNase I (Invitrogen) for 15 min at room temperature and 
inactivated by the addition of 2.5 mM EDTA followed by incubation at 65°C for 10 
min according to the manufacturer’s instructions. The DNase-treated RNA was 
subsequently reverse transcribed in 20 µl reactions containing the following reagents 
from Invitrogen; 250 ng of Oligo(dT) primer, 1 × First Strand Buffer, 10 mM DTT and 
500 µM of each dNTP and 100 U Superscript II. cDNA synthesis was allowed to 
proceed for 1 h at 42°C before inactivation at 72°C for 10 min.   
 
 
3.2.5 Real-time PCR and data analysis 
In paper I, TaqMan PCR amplification reactions were performed using TaqMan 
Universal Master mix and 250ng of cDNA in MicroAmp Optical Plates with 
MicroAmp Optical Adhesive Film (Applied Biosystems). Quantitative PCR was 
performed using the Fast Real-Time PCR System (Applied Biosystems) with 
incubations at 50°C for 2 min. and at 95°C for 10 min. to activate the AmpliTaq 
polymerase, followed by 40 cycles at 95°C for 15 s and 60°C for 1 min. Pre-developed 
specific primers (TaqMan® Gene Expression Assays, Applied Biosystems,) were used 
to detect IDO1 (Assay ID Hs00158027_m1) and TDO2 (Assay ID Hs00194611_m1) 
and HPRT1 (Assay ID Hs01003270_g1).  
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Sample threshold cycle (Ct) values in standard curve samples containing IDO1, TDO2 
and HPRT1 mRNA (paper I) were used to calculate the cDNA concentration 
equivalents in the test samples. Gene expression data of the gene of interest was then 
normalized to HPRT1 reference gene expression to obtain relative concentration and is 
presented as relative units. In paper III, one µl cDNA templates were added to 
triplicate 25 µl reaction mixtures using Platinum SYBR® Green qPCR Supermix UDG 
(Invitrogen). An ABI Prism 7500 real-time thermocycler was used (Applied 
Biosystems, Palo Alto, CA, USA). Primers (Invitrogen) are provided in Table 1. 
Threshold cycle (Ct) values from the exponential phase of the PCR amplification plot 
for each target transcript was normalized to that encoding glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). From these values, fold-differences in the levels of 
transcripts between individual untreated and treated cell cultures were calculated 
according to the formula 2-∆∆Ct (Livak and Schmittgen, 2001). 
 
 
Table 1. Gene symbols and primer sequences for transcripts analyzed by real-time PCR in 
paper III. 
 
 
Several studies have shown that infections activate the
KP, which thereby appear to serve both as a direct
defense mechanism and as a means of modulating the
immune response [1,21]. The enzyme indoleamine 2,3-
dioxygenase (IDO1) is the first and rate-limiting step of
this pathway and is highly induced by the pro-inflamma-
tory cytokine interferon (IFN)-g [22,23]. However, it is
not clear if pro-inflammatory cytokines affect expression
of genes encoding other enzymes of the KP. While
human fibroblasts have previously been employed for
studying the role of IDO1 in controlling experimental
infections [24-26], expression or functionality of genes
encoding downstream enzymes in the KP have not been
investigated in such cells. Since alterations in the KP
may potentially reflect the pathophysiology of several
neuropsychiatric disorders, it is of major importance to
study the KP in primary cells obtained from humans. In
the present study, we have established human ex vivo
skin fibroblast cell cultures as a successful approach to
study the KP. We investigated if transcripts encoding
enzymes in the kynurenine pathway can be detected in
these cells and if their relative abundances are modu-
lated by IFN-g and/or tumor necrosis factor (TNF)-a.
Materials and methods
Tissue isolation and culture
To establish fibroblast cultures, a cutaneous biopsy was
taken from the arm of seven consenting volunteers
recruited at Karolinska University Hospital Huddinge.
Biopsies were minced and placed in 35 mm dishes
(Corning Incorporated, Corning NY, USA) under a ster-
ile glass coverslip and cultured in DMEM Glutamax, 10
mM HEPES, 1X MEM amino acids, 1X sodium pyruvate
supplemented with 100 U/ml penicillin, 100 μg/ml
streptomycin, 15% fetal calf serum (all from Invitrogen,
Paisley, UK), in a humidified 37°C, 5% CO2 incubator.
The regional ethics committee approved the study (04-
273/1, supplements 2006/637-32 and 2009-06-12).
Cytokine treatment
After 2 passages, cells were seeded into 6-well plates
(Corning Inc.). At confluence, cytokine treatment was
performed during 48 hours using human recombinant
TNF-a 100 U/ml or IFN-g 200 U/ml (PeproTech, Lon-
don, U.K.) in serum-free media, otherwise as above.
Experiments were ended by removal and freezing of the
supernatants and addition of lysis buffer to the cell
monolayer, see below.
RNA extraction and reverse transcription
Total RNA was extracted from the cells using the
RNeasy Mini kit (Qiagen, GmbH, Hilden, Germany).
The amount and purity of the RNA was assessed by
spectrophotometry using a Nanodrop ND-1000
(NanoDrop Technologies, Wilmington, DE, USA). Total
RNA (250 ng) was subsequently treated with 1 unit of
amplification grade DNase I (Invitrogen) for 15 min at
room temperature and inactivated by the addition of 2.5
mM EDTA followed by incubation at 65°C for 10 min
according to the manufacturer’s instructions. The
DNase-treated RNA was subsequently re r e tran-
scribed in 20 μl reactions containing the following
reagents from Invitrogen; 250 ng of Oligo(dT) primer, 1
× First Strand Buffer, 10 mM DTT and 500 μM of each
dNTP and 100 U Superscript II. cDNA synthesis was
allowed to proceed for 1 h at 42°C before inactivation at
72°C for 10 min.
Real-time PCR and data analysis
One μl cDNA templates were added to triplicate 25 μl
reaction mixtures using Platinum SYBR Green qPCR
Supermix UDG (Invitrogen). An ABI Prism 7500 real-
time thermocycler was used (Applied Biosystems, Palo
Alto, CA, USA). Primers (Invitrogen) are provided in
Table 1. Threshold cycle (Ct) values from the exponen-
tial phase of the PCR amplification plot for each target
transcript were normalized to that encoding glyceralde-
hyd-3-phosphate dehydrogenase (GAPDH). From these
values, fold-differences in the levels of transcripts
Table 1 Transcripts analyzed by real-time PCR, gene
symbols and primer sequences
Target
transcript
Gene Polarity Sequence (5’®3’)
IDO1 INDO Sense GCATTTTTCAGTGTTCTTCGCATA
Anti-sense CATACACCAGACCGTCTGATAGCT
TDO TDO2 Sense GAACATCTTTTTATCATAACTCATCAAGCT
Anti-sense ACAACCTTAAGCATGTTCCTTTCAT
KMO KMO Sense TGTAATCCTCCAAGCTTCAATCTG
Anti-sense CTAGTAGATGCCCACTGAATATTTGTG
HAAO HAAO Sense GGACGTTCTGTTTGAGAAGTGGTT
Anti-sense AGCTGAAGAACTCCTGGATGATG
KAT1 CCBL1 Sense CCTGCTAAGGCTCAGGTATAACCT
Anti-sense GGACTCAAGCCTAAAGGCAACTC
KAT2 AADAT Sense CACATCTGGCAGCCAACAAG
Anti-sense CACTGGCAACATTAATAATGTTGCA
KAT3 CCBL2 Sense ACTATCAGCCATCCCCGTTTC
Anti-sense AATGAAGCAAAAACGCACAAACT
KAT4 GOT2 Sense TGTGGTGTGCAGCCTCTCAT
Anti-sense AAGCCTGAACCCAGCTAGCA
KYNU KYNU Sense ACAGGATCTGCCTCCAGTTGA
Anti-sense TGGCCCACTTATCTAGTTCTTCTTC
QPRT QPRT Sense ACACCGGCCATGGGTTAAC
Anti-sense GCCCCATTGGCCACTGA
GAPDH GAPDH Sense CACATGGCCTCCAAGGAGTAA
Anti-sense TGAGGGTCTCTCTCTTCCTCTTGT
Asp et al. Journal of Inflammation 2011, 8:25
http://www.journal-inflammation.com/content/8/1/25
Page 2 of 7
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3.2.6 Protein extraction and Western Blotting 
In paper I, total protein was extracted using ice-cold lysis buffer (50 mm Tris buffer, 
pH 7.4, containing 0.5% Triton X-100, 150mm NaCl, 1 mM EDTA and protease 
inhibitors) and homogenized by sonication. After centrifugation the supernatants were 
mixed with loading buffer; 10X Orange Loading Dye for Odyssey (Licor; 929-10100) 
or 4X Loading Dye (NuPage; NP0007) for film, denatured at 95°C for 5 minutes, 
subjected to NuPAGE 10% or 4-12% Bis–Tris gel electrophoresis and then 
electrophoretically transferred to nitrocellulose membranes (Invitrogen, LC2001). 
Membranes were blocked in 5% non-fat milk (Bio-Rad 170-6404) in Tris buffered 
saline with 1% tween (TBS-T) or Odyssey blocking buffer (927-40000) for 1 hour prior 
to antibody labeling. The membrane was incubated with primary antibody against 
TDO2 (1:2000) or IDO1 (1:1000) over night in 4°C, washed in TBS-T and then 
incubated with secondary antibody for 1 hour in room temperature. Following wash in 
TBS-T, membranes were developed using either the Licor Odyssey scanner or 
SuperSignal West Pico Chemiluminescence substrate (SuperSignal, Pierce 
Biotechnology, Inc., Rockford, IL, USA, 34080). Protein levels were normalized to β-
actin (1:5000) and blots were analyzed using Quantity One 1-D Analysis Software 
(Bio-Rad). 
 
 
3.2.7 Immunocytochemistry 
In order to investigate cell purity of cultures in paper I, cells were cultured on cover 
slides coated with Poly-L-lysine (P4707) and laminin (L2020; both from Sigma). Cells 
were serum starved for 24 hours and then fixed in 4% paraformaldehyde in phosphate 
buffer for 15 minutes. After permeabilization in PBS containing 0.1% Triton-X100 
(PBS-TX) for 5 minutes, the cells were blocked in PBS-TX containing 5% normal goat 
serum for 1 hour in room temperature. Cells were then incubated with primary 
antibodies against GFAP, Iba1, NeuN, S100B, nestin and vimentin (1:100) in PBS-TX, 
over night in 4°C. To further investigate the protein expression of IDO1 and TDO2 in 
these cells (paper I), they were also labeled with antibodies against these proteins 
(IDO1 and TDO2 1:100), following IL-1β (10ng/ml) stimulation for 48 hours. Cells 
were washed with PBS and then incubated with Alexa Fluor® conjugated secondary 
antibodies for 1 hour at room temperature. Following antibody incubation, cover slides 
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were dried and mounted on glass slides using cover slip mounting medium containing 
DAPI (Prolong Gold with DAPI, P36934, Invitrogen). Confocal images were captured 
using a confocal microscope system (Zeiss, LSM 710, Munich, Germany) operated by 
LSM software ZEN 2009.  
 
 
3.3 HUMAN SUBJECTS 
In paper I, subjects were collected from several sources. For sample I, patient data 
were collected from euthymic bipolar disorder patients that were enrolled in a long-term 
follow-up program (St. Göran bipolar project) at a bipolar outpatient unit at the 
Northern Stockholm psychiatric clinic. Sample II consisted of patients from St. Göran 
bipolar project who did not undergo lumbar puncture as well as patients with clinical 
diagnosis of bipolar disorder I from Karolinska Hospital in Huddinge or from ordinary 
psychiatric outpatient units in Stockholm. The diagnostic procedure has been outlined 
in detail previously. All included subjects had been diagnosed with either bipolar 
disorder I or bipolar disorder II.  
 
The analyses included all subjects with existing data (not all patients volunteered to 
undertake all investigations). All patients, and their parents, in sample I were born in 
Sweden.  
 
The 46 general population controls were randomly selected by Statistics Sweden. All 
were born in Sweden and by parents also born in Sweden.  
 
Sample II consisted of 420 patients with bipolar disorder I, 108 patients with bipolar 
disorder II, 32 patients with bipolar disorder none otherwise specified, and 5 patients 
with schizoaffective disorder of bipolar type. The mean age in this sample was 50±16 
years and 70% were females. 59% of the patients in sample II had a history of 
psychosis compared to 47% in sample I. This difference may be related to a higher 
proportion of bipolar disorder I and to a broader definition of psychosis in sample II.  
 
In sample III, patients contributing with data in the analyses of CSF IL-1β were also 
from the St. Göran bipolar project. Controls were collected at Linköping University 
Hospital (Sweden). Cytokine levels of healthy volunteers were analyzed and published 
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in a previous study (Söderlund et al., 2011). Three of a total of 30 patients were here 
excluded. One of these three patients had an alcohol abuse and a cardiovascular disease 
(CSF IL-1β concentration 10.31 pg/ml, the patient classified as psychotic), one had 
persistent auditory hallucinations, suspected cannabis and alcohol abuse (CSF IL-1β 
concentration 9.97 pg/ml, the patient classified as psychotic), and finally one at the age 
of 73 had a cerebrovascular disease (CSF IL-1β concentration 0.73 pg/ml, the patient 
classified as psychotic).  
 
In paper II, Twenty-two Swedish Caucasian outpatients, diagnosed with schizophrenia 
(n = 18; 11 males, 7 females) or schizoaffective disorder (n = 4; 2 males, 2 females), 
according to the Diagnostic and Statistical Manual (DSM)-IV criteria were included in 
the study. All patients were recruited from an outpatient clinic located at Linköping 
University hospital (Sweden). All of the patients were prescribed olanzapine as the only 
antipsychotic drug. The patients had been on medication with olanzapine for between 
0.1 and 11 years (median 2 years) using the same dose (5–25 mg/day) for at least 14 
days prior to CSF sampling. Mean (± SD) age of patients was 37.1 ± 7.6 years (range 
23–50 years). Full details of the study design and patient characteristics, including 
serum and CSF concentrations of olanzapine, have been published elsewhere (Skogh et 
al., 2011). As controls, 26 healthy Caucasian volunteers (18 males, and 8 females in the 
follicular phase of the menstrual cycle) were recruited among medical students, hospital 
staff, and their relatives. Controls were not allowed to use any medication for at least 
one month prior to sampling; however, coffee and smoking were allowed. The mean  
(± SD) age of the controls was 24.9 ± 5.8 years (range 18–49 years).  
 
In paper III seven consenting volunteers recruited at Karolinska University Hospital 
Huddinge were used to establish fibroblast cultures from a cutaneous biopsy from the 
arm. 
 
In paper IV thirteen twin pairs were recruited from a nationwide cohort of Swedish-
born, same-sex twins with schizophrenia, bipolar disorder and healthy control-pairs 
ascertained through the Swedish Twin Registry. In four of the included twin-pairs 
neither proband nor co-twin was affected by bipolar disorder, schizophrenia or 
schizoaffective disorder. The sibling of one of the 26 recruited twins did not agree to 
participate in the lumbar puncture. None of the participants was hospitalized at the time 
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of examination. Prior to analysis two CSF samples were lost due to experimental error, 
leaving in total ten pairs and three single twins for analysis. 
 
3.3.1 Assessment of subjects 
In paper I medical chart reviews, and in some cases interviews with the treating 
physician were performed in addition to the collected research data, in order to assure a 
high diagnostic validity. In sample I the clinical diagnosis of bipolar disorder was 
established according to the Affective Disorder Evaluation (ADE), which was 
previously used in the STEP-BD project (Sachs et al., 2003). The ADE was translated 
and modified to suit Swedish conditions. To minimize inter-rater variability, the 
collected information was presented at a diagnostic case-conference, and a consensus 
panel of experienced board-certified psychiatrists who specialize in bipolar disorder 
made the final diagnostic decision at this conference. CSF samples where collected 
when the patients were symptom free and in a stable euthymic mood, as judged by a 
physician. For ethical reasons, the patients continued to take their prescribed 
medication.  
 
Control subjects in sample I and II of paper I underwent a psychiatric interview by 
experienced clinicians using the M.I.N.I. to exclude psychiatric disorders (Sheehan et 
al., 1997). Moreover the controls completed the same investigations the patients had 
undertaken, including self-rating scales, somatic tests, blood tests, and lumbar puncture. 
Because the assessments of controls might reveal pathological findings, case 
conferences were held between examining clinicians, primary investigator, and the 
study coordinator to decide whether or not to include such persons in the study. It was 
thus decided to allow past minor depressive episodes, isolated episodes of panic 
disorder, eating disorders, or obsessive compulsive disorder that had remitted 
spontaneously or with brief psychotherapy counseling. Substance abuse was screened 
for at the telephone interview by the nurse, in the psychiatric interview, by AUDIT and 
DUDIT, as well as by determining serum levels of carbohydrate-deficient transferrin 
(Saunders et al., 1993). 
 
Overconsumption of alcohol as revealed by carbohydratedeficient transferrin or 
responses indicating large consumption (48 standard drinks per time more than 2 times 
per week) and/or amnesia and/or loss of control more than once per month resulted in 
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the exclusion of these individuals from the study. Other exclusion criteria were 
neurological conditions other than mild migraines, untreated endocrinological disorders, 
pregnancy, dementia, recurrent depressive disorder, and suspected severe personality 
disorders (based on interview and SCID-II personality assessment) and a family history 
of schizophrenia or bipolar disorder in first-degree relatives. Individuals with a severe 
inflammatory disease (peripheral or central), a brain disease, and an ongoing drug 
treatment that could influence the immune system, or who fulfilled criteria for a DSM-
IV-TR disorder were not allowed to participate as controls (Jakobsson et al., 2013).  
 
In sample II, lifetime manic and depressive symptoms were assessed based on 
interviews and medical records focusing on the most severe manic episode using the 
modules for mania and depression in the Schedules for Clinical Assessment in 
Neuropsychiatry (SCAN; Wing et al., 1990). Phenotypes such as lifetime psychotic 
features during manic or depressive episodes were also assessed.  
 
36 healthy male volunteers used in sample III of paper I and in paper II, were 
recruited from among medical students, hospital staff members and their relatives. They 
all underwent a medical check-up including laboratory tests (electrolytes, blood, 
thyroid, kidney and liver) and a physical examination. The volunteers were free of 
medication for at least 1 month and free from any form of substance abuse. Smoking 
and coffee was allowed. The volunteers underwent a semi-structured interview using 
the Structured Clinical Interview for DSM-IV Axis I disorders (SCID-I First et al., 
1997a). The interview was directed toward affective disorders, anxiety disorders and 
drug abuse. The volunteers also completed the SCID-II questionnaire for personality 
disorders (First et al., 1997b). 30 healthy volunteers were considered to be eligible for 
inclusion in the study with respect to the clinical interview and SCID results. All were 
considered healthy by the psychiatrist performing the examinations and showed no 
signs of psychiatric or somatic illness or had any laboratory test results outside of the 
standardized reference ranges. None of the volunteers had a family history of major 
psychosis or suicide in first- or second-degree relatives.  
 
For patients recruited from the St. Göran bipolar project, psychosis was strictly defined 
as hallucinations and/or delusions, not caused by a psychotropic substance as judged by 
the physician, and in an affective episode, thus fulfilling the criteria according to DSM-
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IV-TR. For patients recruited from the outpatient unit at Karolinska Hospital in 
Huddinge or from ordinary psychiatric outpatient units in Stockholm the definition of 
psychosis was 'loss of reality and delusions, hallucinations or paranoia during manic or 
depressive episodes according to DSM-IV. Control subjects underwent the same 
clinical evaluation as patients and could choose in which other investigations to 
participate  
 
In sample I of paper I, an experienced psychologist performed neuropsychological 
assessments in conjunction with the lumbar puncture. In the Trail Making Test (TMT) 
from the Delis-Kaplan Executive Functioning System (D-KEFS), Number Sequencing 
(connecting the numbers 1-16) and Letter Sequencing, (connecting the letters A-P) was 
first extracted. The “Switching cost” was the total time taken for combined 
letter/number switching minus the Combined Number Sequencing + Letter Sequencing. 
These variables are extracted as raw scores and then converted to a contrast score in 
which the scaled score 10 is average in the normal population, with 7-13 reflecting +/- 1 
SD and lower scores are reflecting difficulties in set shifting thought to capture 
cognitive inflexibility. The derived scores are thought to enhance the test’s sensitivity to 
executive functioning while minimizing the influence of non-cognitive factors. 
 
In paper II, All patients were somatically healthy, as judged by routine laboratory 
analyses (electrolytes, hematology, kidney, liver, and thyroid function) and a physical 
examination. The Brief Psychiatric Rating Scale (BPRS; Overall and Gorham, 1962) 
and Global Assessment of Functioning (GAF; American Psychiatric Association, 1994) 
index were used to evaluate symptoms and the level of function, respectively.  
 
In paper IV all twin individuals were interviewed with SCID-I for DSM-IV Axis I 
Disorders (First et al., 1997a) and SCID-II for DSM-IV Axis II Disorders (First et al., 
1997b). Information about socioeconomic status, smoking habits, and current 
medication was collected. Psychiatric symptoms were rated using the following scales: 
Scale for Assessment of Negative Symptoms (SANS; Andreasen, 1983), Scale for 
Assessment of Positive Symptoms (SAPS; (Andreasen, 1984), Schizotypal Personality 
Questionaire (SPQ-B; Raine and Benishay, 1995), Hamilton Depression Rating Scale 
(HDRS; Williams, 1988), and Young Mania Rating Scale (YMRS; Young et al., 1978). 
The Global Assessment Function (GAF; American Psychiatric Association, 1994) was 
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used to assess DSM-IV Axis V. Because collection of the CSF in the twin participants 
was performed two months or more after the psychiatric assessment described above, a 
psychiatrist performed a complementary SPQ-B assessment adjacent to the CSF-
collection to update information about psychiatric status, current medication and 
somatic status. Also information about heredity, age of onset, insight, period of active 
symptoms and lifetime somatic diagnosis was collected. Finally two clinically 
experienced researchers with access to information of the diagnostic assessments, 
medical records and a full history of lifetime psychiatric diagnostic codes of the 
Hospital Discharge Registry (1973–2009), but with no access to the CSF-results, 
decided on a final consensus diagnosis. 
 
 
3.3.2 Zygosity determination  
In paper IV, the zygosity of the twins, mono- or dizygotic, was validated using a robust 
panel of 47 highly multiplexed single nucleotide polymorphisms (SNPs) that provide 
reliable and high quality data on a range of different DNA templates (Hannelius et al., 
2007). Of the 13 twin pairs recruited for the study, 7 were monozygotic and 6 dizygotic.  
 
 
3.3.3 Database studies - Postmortem samples 
In paper I, a post-mortem brain tissue collection deposited in the Braincloud database 
(http://braincloud.jhmi.edu) was used to study co-expression of SNX7 and CASP8. Data 
on 272 postmortem tissue homogenates of dorsolateral prefrontal cortex (DLPFC; i.e., 
BA46/9) from healthy donors were obtained. The sample and the methods are 
previously described (Colantuoni et al., 2011). Levels of CASP8 mRNA in relation to 
psychosis in bipolar disorder were studied using data obtained from the Stanley Medical 
Research Institute (SMRI) database (www.stanleygenomics.org). A prior meta-analysis 
(Elashoff et al., 2007) of 105 DLPFC (BA 46) samples using the SMRI microarray 
collection was queried comparing bipolar disorder cases with psychotic features to 
bipolar disorder cases without psychotic features. Diagnosis was here made according 
to DSM-IV-TR.  
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3.3.4 Rating Scales 
There are several scales rating the severity of schizophrenia symptoms. Some 
frequently employed are the Positive and Negative Syndrome Scale (PANSS; Kay et 
al., 1987), The Scale for the Assessment of Positive Symptoms (SAPS; Andreasen, 
1984), the Scale for the Assessment of Negative Symptoms (SANS; Andreasen, 1983) 
and the Brief Psychiatric Rating Scale (BPRS; Overall and Gorham, 1962). There are 
also scales rating symptoms in the schizotaxic range (Meehl, 1962), used to assess the 
presence of schizotypic, schizoid and paranoid personality disorders, such as the cluster 
A of the Structured Clinical Interview for the DSM-IV Axis II personality disorders 
(SCID-II), and the SPQ-B (Raine, 1991; Raine and Benishay, 1995).  
In paper IV potential correlations between SANS, SAPS, SPQ-B, and SCID-II on one 
hand and CSF metabolites and cytokines on the other hand are investigated. Therefore 
these four scales will be shortly described.  
 
3.3.4.1 SANS and SAPS 
The SANS and the SAPS are composed of nine subscales, measuring the severity of 
delusions, hallucinations, positive formal thought disorder and bizarre behavior on the 
positive scale, and deficit symptoms such as avolition, anhedonia, flat affect, alogia and 
attentional disturbances on the negative sub-scale. Every sub-scale contains varying 
number of items, as well as a global rating for the specific sub-scale.  Since the 
development of these scales, several studies claiming the presence of more than two 
dimensions of schizophrenia symptoms have been published (Arndt et al., 1991; 
Klimidis et al., 1993; Minas et al., 1992). 
 
3.3.4.2 SPQ-B 
The SPQ is a self-report questionnaire composed of nine sub-scales measuring different 
schizotypal traits. Originally the questionnaire was composed of 74 items, but has now 
been improved to contain only 22 items representing three sub-scales in the SPQ-Brief. 
The subscales measure cognitive-perceptual factors, interpersonal factors and 
disorganization factors (Raine and Benishay, 1995). 
 
3.3.4.3 SCID-II 
The SCID-II is a questionnaire for the evaluation of Axis-II personality disorders. It is 
composed of a questionnaire to be completed by the patient that is used as a screening 
Magdalena Kegel 
 47 
tool to shorten the subsequent interview. The questionnaire evaluates the presence of 
twelve different personality disorders. Cluster A contains the scales to measure the 
presence of schizoid, paranoid and schizotypal personality disorder and are used in this 
thesis.   
 
 
3.4 CSF ANALYSES 
3.4.1 Lumbar Puncture 
In paper I and II, lumbar puncture was performed on all participants between 8 am and 
11 am after a night of fasting and bed-rest. A disposable needle (BD Whitacre Needle, 
0.7 × 90 mm) was inserted at the L4–L5 level. In paper I, a volume of 12 mL of CSF 
was collected, inverted to avoid gradient effects, divided into aliquots and stored at –
70°C until analyzed. In paper II, CSF was allowed to drip into a plastic test tube. The 
CSF samples were protected from light, centrifuged at 1438 g for 10 minutes (Sigma 
203 centrifuge) within 30 minutes after the puncture, and divided into 2-to 3-ml 
aliquots. Samples were stored at −70 °C pending analysis. 
 
The same neurologist performed the 25 lumbar punctures in paper IV, with all subjects 
in a sitting position. Sixteen twin pairs were examined on the same day and the 
remaining two pairs within the same month. The skin in the lumbar region was washed 
with sterile cotton swabs and chlorhexidine 5 mg/mL (Fresenius Kabi, Homburg, 
Germany) before puncture. A disposable needle (Becton Dickinson (BD) 22 GA 3.00 
IN, 0.70675 mm or BD Whitaker Needle 25 GA 3.50 IN, 0.50690 mm was inserted in 
vertebral interspace L3-4, or L4-5, and the very first 12 drops of CSF, approximately 
0.6 mL, were collected in a sterile test tube for microscopic examination. The following 
12 mL of CSF were allowed to drip spontaneously, or by suction six times using a 2 mL 
syringe due to slow flow, in a second test tube, which was gently inverted 10 times to 
secure homogeneous mixing of the components to avoid gradient effects.  
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3.4.2 Analysis of KYNA  
Analysis of KYNA in CSF samples (papers I, II, III, IV) was performed using an 
isocratic reversed-phase high-performance liquid chromatography (HPLC) system, 
including a dual-piston, high-liquid delivery pump (Bischoff Chromatography), a 
ReproSil-Pur C18 column (4 × 150 mm, Dr. Maisch GmbH ) and a fluorescence 
detector (Jasco Ltd.) with an excitation wavelength of 344 nm and an emission 
wavelength of 398 nm (18 nm bandwidth), essentially as previously described.26 A 
mobile phase of 50 mM sodium acetate (pH 6.2, adjusted with acetic acid) and 7.0% 
acetonitrile was pumped through the reversed-phase column at a flow rate of 0.5 
mL/min. Samples of 50 µL were manually injected (Ecom). Zinc acetate (0.5 M not pH 
adjusted) was de- livered after the column by a peristaltic pump (P-500; Pharmacia) at a 
flow rate of 0.10 mL/min. Signals from the fluorescence detector were transferred to a 
computer for analysis with Datalys Azur (version 4.6.0.0; http://datalys.net). The 
retention time of KYNA was about 7–8 minutes. Initially, the sensitivity of the system 
was verified by analysis of a standard mixture of KYNA with concentrations from 0.5 
to 30 nM, which resulted in a linear standard plot. To verify the reliability of this 
method, some samples were analyzed in duplicate, and the mean intra-individual 
variation was below 5% 
 
In paper I, cell culture supernatants were collected and immediately frozen on dry ice 
and kept in -20°C until analysis. In order to precipitate residual protein, samples were 
centrifuged at 14000 rpm for 5 minutes and an equal volume of perchloric acid (0.4M) 
was added to the supernatants. The centrifugation procedure was repeated followed by 
addition of 70% perchloric acid and centrifugation 2 more times. Analysis of KYNA 
was performed as described for CSF samples with some modifications. Initially, the 
sensitivity of the system was verified by analysis of a standard mixture of KYNA with 
concentrations from 0.25 to 30 nM, which resulted in a linear standard plot. The lower 
detection limit of the system was set to 0.625 nM, and samples below this limit are 
reported as undetectable.  
 
In paper III, fibroblast cell culture supernatants (1.0 ml) were collected and kept in -
20°C until analysis. In order to precipitate residual protein, samples were centrifuged at 
20800 g for 5 minutes and an equal volume of 0.4 M perchloric acid was added to the 
supernatants. After a second centrifugation 70% perchloric acid (300 µl) was added, 
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and thereafter the supernatants were centrifuged twice at 20800 g for 5 minutes. 
Analysis was performed as in paper I.  
 
 
3.4.3 Analysis of kynurenine 
To analyze kynurenine (paper II) samples were thawed in 4°C and 50µl were manually 
injected (Rheodyne, Cotati, California) into a HPLC system. Separation was achieved 
by reversed-phase liquid chromatography using a 20mM NaH2PO4 buffer (not pH 
adjusted) with 5.0% acetonitrile. The mobile phase was delivered by an HPLC pump 
(Bischoff Chromatography, Leonberg, Germany) through a ReproSil-Pur C18 column 
(4 3 150 mm, Dr Maisch GmbH, Ammerbuch, Germany) at a rate of 0.5 ml/min. 
Following separation, the analysate was first passed through a guard cell with an 
oxidizing potential of 50 mV. Samples were then quantified by sequential oxidation and 
reduction in a high-sensitivity analytical cell (ESA 5011; ESA Inc., Chelmsford, 
Massachusetts) controlled by a potentiostat (Coulochem III; ESA Inc.) with an applied 
potential of 600 mV for detection of kynurenine. The signals from the detector were 
transferred to a computer for analysis (Datalys Azur, Grenoble, France). The retention 
time of kynurenine was approximately 8–9 minutes. The sensitivity of the system was 
verified by analysis of standard mixtures of kynurenine, with concentrations from 5 to 
100nM, resulting in a linear standard plot. 
 
 
3.4.4 Analysis of tryptophan and quinolinic acid 
In paper II, the analysis of tryptophan was performed as described for kynurenine. The 
retention time was approximately 15–16 minutes and the sensitivity of the system was 
verified by analysis of standard mixtures of tryptophan, with concentrations from 0.5 to 
5µM, resulting in a linear standard plot.  
 
In paper IV, analysis of tryptophan and quinolinic acid was performed using For 
QUIN, standard curves were prepared in the range of 0.005 to 0.5 µmol/L QUIN 
(Sigma-Aldrich), dissolved in Dulbecco´s Phosphate Buffer Saline (PBS; Gibco®, Life 
Technologies, Carlsbad, CA, USA), aliquoted and stored at -70°C until use. CSF and 
standard samples (50µL) were diluted 2x with internal standard solution in 5% formic 
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acid and filtered at 3000 g for 60 minutes at 10°C using 10 kDa Ultracel®-10 filter 
plates (Merck Millipore, Darmstadt, Germany). QUIN, TRP, D5-TRP was purchased 
from Sigma-Aldrich (St. Louis, MO, USA) and the Internal Standard (13C315N1-
QUIN) from Synfine research Inc., (Ontario, Canada) Internal standard was added to 
each standard and CSF sample to a final concentration of 0.5 µmol/L. Following 
centrifugation 7.5 µL of the filtrate was injected into a Waters Acquity HPLC system 
equipped with a SymmetryShieldTM RP18 2.1 × 100mm, 3.5µm particle column. The 
detection was performed using a Waters Xevo TQ-S triple quadrupole mass 
spectrometer operating in positive ionization MS/MS configuration. The mobile phase 
was run at a flow rate of 300 µL/minute and consisted of 2.1% formic acid (MS-grade, 
Sigma-Aldrich) in MilliQ water (A phase) and 95% acetonitrile (MS-grade, Sigma-
Aldrich), 0.1% formic acid in MilliQ water (B phase), starting with 5% B for 2 minutes, 
following gradient elution up to 95% B, with a total run time of 10 minutes. The mass 
spectrometer was tuned for quinolinic acid and tryptophan and set at capillary voltage 
of 3.0V, cone voltage 6 and 18 V for quinolinic acid and tryptophan respectively, 
source temperature 150°C, desolvation temperature 500°C, desolvation gas flow of 
1000 L/hr and collision energy of 16 eV. Mass spectral transition for quinolinic acid 
and tryptophan was m/z 168> 106; 205 > 118 and for the IS 172> 110; 210 > 123.  
 
Calibration was performed using standards covering the range of the CSF 
concentration. Seven concentration points were used to establish a linear calibration 
curve and plotted using the ratio of analyte peak area over IS peak area after integration 
by Masslynx 4.1 software (Waters Corporation, Milford, MA, USA). Retention times 
for quinolinic acid and tryptophan was 1.2 and 3.6 minutes respectively. 
 
 
3.4.5 Analysis of HVA and 5-HIAA 
In paper I and IV the analysis of HVA and 5-HIAA was performed using selected ion 
monitoring with deuterium-labelled internal standards. To 0.2 ml of CSF, 400 pmol of 
[D3]-HVA and 200 pmol of [D2]-5-HIAA were added as internal standards. The 
samples were acidified with 4 M formic acid and saturated with sodium chloride before 
extraction twice with 0.5 ml of diethyl ether. The combined diethyl ether phases were 
evaporated under a stream of nitrogen and the derivatives were prepared by the addition 
of 20% pentafluoropropanol in pentafluoropropionic anhydride (50µl). The samples 
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were heated for 15 minutes at 75°C and were then evaporated in a desiccator under 
vacuum. Subsequently, pentafluoropropionic anhydride (50 µl) was added and allowed 
to react for another 5 minutes at 75°C. The reagent was again evaporated and the 
residue was dissolved in ethyl acetate (25 µl) (Swahn et al., 1976). After preparations 
the analysis was performed on a Finnigan 3200 GC-MS system (Blennow et al., 1993). 
 
 
3.4.6 Analysis of cytokines 
In paper I a sandwich immunoassay-based protein array multi plex system (Invitrogen 
AB) was used. It presented a guaranteed lowest detection limit of 1 pg/mL for each 
cytokine to quantify IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, granulocyte-macrophage 
colony-stimulating factor (GM)-CSF, IFN-γ and TNF-α. The samples were incubated 
with beads coated with the specific antibodies. Thereafter incubations were conducted 
with biotin-conjugated antibodies and streptavidin-phycoerythrin. Standard curves 
(Biosource International) ranging from 0.38 pg/mL to 1025 pg/mL of the respective 
cytokine were used for quantification. A Luminex reader (Luminex Corporation) was 
used to simultaneously quantify the concentrations of the cytokines. 
 
In paper IV, CSF samples used for cytokine analysis had previously been thawed once. 
IL-1β, IL-6, IL-8 and TNF-α, was quantified in CSF using a customized Human Ultra-
Sensitive 4-Plex Kit (MesoScale Discovery®, Gaithersburg, MD, USA) in 2012. The 
assays were analyzed as per the manufacturers protocol (http://www.mesoscale.com), 
with the modification of a longer primary incubation time (over night at 4°C) and a 
sample volume of 50 µl. Intra-assay coefficient of variation was below 20% for all 
analytes presented. The limit of detection (LOD) in our analysis were: IL-1β (0.19 
pg/ml), IL-6 (0.05 pg/ml), IL-8 (0.04 pg/ml) and TNF-α (0.08 pg/ml).  
 
 
3.5 GENOTYPING AND QUALITY CONTROL 
Genotyping was done as part of enrollment of this cohort in a large multi-center GWAS 
effort. Subjects in sample I and in the control sample were genotyped using the 
Affymetrix 6.0 array (Santa Clara, CA, USA) at the Broad Institute in Boston, MA. 
Subjects in sample II were genotyped using the Affymetrix 6.0 chip or the Illumina 
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OmniExpress chip. Blood samples were obtained and DNA extracted from whole blood 
using standard methods at the Karolinska Institutet. SNPs were excluded for marked 
departure from Hardy-Weinberg equilibrium (P<1x10-6), low minor allele frequencies 
(<1%), and non-random genotyping failure, inferred from the flanking haplotype 
background using the PLINK ‘mishap’ test (P<1x10-10). Plate-based associations of 
P<1x10-6 were taken as evidence of non-random plate failure, based on a comparison of 
allele frequency of each plate to all others and were removed on a plate-by-plate basis. 
(Bergen et al., 2012).  
 
 
3.6 STATISTICS 
The primary analysis in the GWAS in paper I was a linear regression of CSF KYNA 
residuals on single-SNP allele dosage. “Genome-wide significant” was set to P<5×10-8. 
Additional analyses with the first four multidimensional scaling (MDS) components as 
covariates to control for population substructure were also performed (Bergen et al., 
2012) but suggest no effects related to genetic diversity. In sample II, the ethnicity of 
the participants was partly unknown and all reported results are adjusted for population 
stratification. In the correlation analyses “r” refers to Pearson´s correlation coefficient if 
not otherwise specified. The assumptions of each test were checked. All reported P-
values are two sided. All analyses were done using the statistical software programs R 
(R Development Core Team, Vienna, Austria), IBM SPSS Statistics 20.0 (IBM SPSS 
Inc., Chicago, IL, USA), the script PROCESS for SPSS (Hayes, 2013), and Graph-
Pad® prism 6.0 (http://www.graphpad.com).  
 
In paper I, plotting CSF QUIN residuals revealed one patient as an outlier in regard to 
CSF QUIN (standardized residuals<3 SD). Data from this 29-year-old male patient 
(CSF QUIN = 85.1 nM) were removed from all further analyses. For one patient the 
QUIN levels were below the lowest level of detection (LLOD), and the QUIN value for 
that patient was substituted for the LLOD value (5 nM). Background characteristics 
between patients and controls were compared using t-tests or Chi-square tests. To study 
the effect of background characteristics on CSF QUIN concentration in the patient 
sample and in the controls sample we used correlation analyses or Mann–Whitney U-
tests. All correlation analyses were performed using Spearman rank correlation tests. 
The comparisons of CSF kynurenine metabolites levels and the QUIN/KYNA ratio 
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between patients and healthy volunteers were performed using t-tests. Logistic 
regression analyses with age and sex as covariates were also performed. All reported P-
values are two sided. All analyses were made using IBM SPSS Statistics 21.0 software 
(IBM SPSS Inc., Chicago, IL, USA). 
 
In paper III, comparisons across treatments were done by repeated measures ANOVA 
with Bonferroni’s Multiple Comparison Test using GraphPad® prism (GraphPad 
Software, Inc., San Diego, CA, USA). 
 
In paper IV, background characteristics between proband and co-twins, and between  
di-, and monozygotic twins were compared using Mann-Whitney U-tests, Chi-square 
tests or Fisher exact tests. To study the effect of background characteristics on levels of 
CSF metabolites in the probands and co-twins we used correlation analyses or Mann-
Whitney U-tests. All correlation analyses were performed using Spearman rank 
correlation tests. 
 
Levels of KYNA, tryptophan, QUIN, HVA, 5-HIAA, IL-6, IL-8 and TNF were log-
transformed to obtain a normal distribution of the data.  
To account for the correlated structure of the data, a linear mixed model with a random 
intercept shared between twins in a pair, was fitted. For every analyzed parameter, 
potential confounders identified in the initial analyses with a P-value<0.1 were included 
as co-variates in the initial model. Co-factors were subsequently removed based on 
significance of co-factors and Akaike’s Information Criterion aiming for a final best-
fitted model with fewer parameters. Age and sex was included as co-variates in all 
analyses. All reported P-values are two sided. All analyses were made using IBM SPSS 
Statistics 21.0 software (IBM SPSS Inc., Chicago, IL, USA). 
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4 RESULTS AND DISCUSSION 
4.1 PAPER I 
4.1.1 Psychotic patients with bipolar disorder have elevated levels of 
CSF KYNA and CSF HVA 
In sample I, CSF KYNA concentration was independent of bipolar disorder subtype 
(P=0.43). An effect of age on CSF KYNA concentration was observed (P=0.002). To 
account for potential age confounding, we used the normally distributed residuals 
from a linear regression of age vs. CSF KYNA when age was indicated as a potential 
confounder. CSF KYNA was measured in 76 bipolar disorder patients of whom 
thirty-six patients had a history of psychosis, while 40 patients had no history of 
psychosis. CSF KYNA was also measured in a control group of 46 healthy volunteers 
randomly selected from the general population. The psychotic, but not the non-
psychotic bipolar disorder patients had a significantly higher mean CSF KYNA 
concentration than controls (P=0.015 and P=0.99 respectively). Moreover, the 
psychotic bipolar disorder group had significantly higher CSF KYNA concentration 
than non-psychotic bipolar disorder patients (P=0.026; Figure 2A).  
 
CSF HVA concentration was successfully determined in 72 of the 76 patients and in 
45 of the 46 healthy controls. A strong positive correlation to CSF KYNA was 
observed in patients (r=0.67, P=9.4x10-11; Figure 2B), and in controls (r=0.65, 
P=1.0x10-6). Similar to the analysis of CSF KYNA, the psychotic bipolar disorder 
group had a significantly higher mean CSF HVA concentration than healthy controls 
(P=0.003), as well as non-psychotic bipolar disorder patients (P=0.024), while no 
significant difference in CSF HVA concentration was seen between controls and non-
psychotic bipolar disorder patients (P=0.81; Figure 2C).  
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Figure 2. CSF concentrations of kynurenic acid (KYNA) in euthymic bipolar disorder 
patients and healthy controls. (A) Mean ± SEM of CSF KYNA levels in 46 healthy psychosis 
(1.72 ± 0.12 nM), and 36 bipolar disorder patients with a history of psychosis (2.08 ± 0.18 
nM). One-way ANOVA with Tukey post hoc tests (using residuals from a linear regression of 
age vs. CSF KYNA); P=9.3x10-3, post hoc tests; controls vs. non-psychotic bipolar disorder, 
P=0.99, controls vs. psychotic bipolar disorder, P=0.015controls (1.60 ± 0.10 nM), and non-
psychotic bipolar disorder vs. psychotic bipolar disorder, P=0.026. (B) The correlation 
between CSF KYNA and CSF HVA (nM) in 72 of these 76 bipolar disorder patients. 
Pearson's r = 0.67; P=9.4x10-11. (C) Mean± SEM CSF HVA concentration in 72 bipolar 
disorder patients with (280 ± 14.4 nM) or without (227 ± 15.6 nM) a history of psychosis in 
comparison to CSF HVA levels in 45 healthy controls (216 ± 10.6 nM). One-way ANOVA 
followed by Tukey post hoc tests revealed that the psychotic bipolar disorder group had a 
significantly higher mean CSF HVA concentration compared to controls (P=0.003), and non-
psychotic bipolar disorder patients (P=0.024), while no significant different in CSF HVA 
concentration was seen between controls and non-psychotic bipolar disorder patients  
(P=0.81). (D) Mean±SEM CSF KYNA in the 51 bipolar disorder patients who underwent 
trail-making test (TMT). The mean CSF KYNA concentration was significantly higher in 
patients that scored below average on the contrast score (<10, n=26; 2.12 ± 0.12 nM) 
compared to patients scoring average or higher (≥10, n=25; 1.62 ± 0.21 nM, P=0.048). Two-
sided P-values, statistical significance set to P<0.05. * P<0.05,** P<0.01,*** P<0.001. 
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4.1.2 CSF KYNA is associated to set shifting performance  
In conjunction with the lumbar puncture, 51 of the 76 euthymic bipolar disorder 
patients agreed to carry out TMT (from the Delis-Kaplan Executive Functioning 
System; D-KEFS) to evaluate executive functions in terms of set-shifting ability. To 
separate the executive component of this test, we used the contrast score of condition 
4 minus condition 1+2. A score of 10 reflects average performance in a normal 
population, while lower scores indicate diminished cognitive flexibility in terms of 
decreased set-shifting ability. The mean CSF KYNA concentration was significantly 
higher in patients that scored <10 compared to patients scoring ≥10 or higher 
(P=0.048, Figure 2D). The use of different pharmacological treatments was equally 
distributed across the two groups. 
 
These findings are in line with previous studies suggesting that KYNA is intimately 
related to dopamine neurotransmission. KYNA has in a number of studies been 
shown to modulate the firing of midbrain dopaminergic neurons (see introduction) 
and CSF KYNA has also previously been shown to correlate with CSF levels of HVA 
(Nilsson-Todd et al., 2007; Nilsson et al., 2007).  These results also support the notion 
of KYNA as a factor linked to psychosis, as the highest levels of both KYNA, and 
HVA were found in patients with a history of psychosis. These results also extend the 
findings that KYNA influences cognitive flexibility in the set shifting paradigm from 
experimental settings (Alexander et al., 2012, 2013), to the clinical reality. As 
cognitive dysfunction is often accompanying psychotic states, this constitutes another 
piece of evidence for the role of KYNA in psychotic disorders. 
 
 
4.1.3 Genome-wide association study 
Despite the modest sample size (n=76), one SNP (rs10158645) located within 
1p.21.3, reached genome-wide statistical significance in relation to CSF KYNA 
(P=2.6x10-8; Figure 3A and 3B). To control for population substructure, we also 
analyzed the association using the first four multidimensional scaling (MDS) 
components as covariates. In line with a low grade of genetic diversity (all subjects 
and their parents were born in Sweden), this yielded a similar result as the unadjusted 
analysis (P=4.33x10-8).  
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The mean CSF KYNA concentration among patients with the T/T genotype (n=55) 
was 1.62 ± 0.095 nM, and in patients with the G/T genotype (n=21) 2.48 ± 0.23 nM. 
The CSF KYNA concentration in the one patient carrying the G/G genotype was 4.75 
nM. 
 
 
Figure 3. Genome-wide association study against kynurenic acid levels in cerebrospinal fluid 
(CSF) of 76 euthymic bipolar disorder patients. (A) Manhattan plot from the GWAS against 
age-adjusted CSF kynurenic acid (KYNA) levels in bipolar disorder. The single nucleotide 
polymorphism (SNP) rs10158645, located within 1p.21.3, reached genome-wide statistical 
significance in relation to CSF KYNA concentration among bipolar disorder patients (β=1.07, 
P=2.58x10-8, MAF=0.15). (B) KYNA levels in carriers of the T/T genotype (n=55), the G/T 
genotype (n=21), and the T/T genotype (n=1) in rs10158645. The y-axis displays residuals 
from a regression of age vs. CSF KYNA concentration (nM).  
 
Analogous to results in bipolar disorder patients, a significant effect of the minor 
allele in rs10158645 on CSF KYNA concentration (adjusted for age) was also seen 
in the control sample (n=46, P=0.036; Figure 4). Including an adjustment for 
population stratification gave a similar result (P=0.021).    
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Figure 4. Levels of CSF kynurenic acid (KYNA) in the 46 healthy controls randomly 
selected from the general population and here stratified on rs10158645 genotype. 37 subjects 
carried the T/T genotype, 9 the G/T genotype while no carriers of the G/G genotype was 
found. Carriers of the G/T genotype had significantly higher CSF KYNA concentration (T/T: 
mean CSF KYNA=1.55±0.11 nM, and G/T: mean CSF KYNA 1.83±0.26 nM; P=0.036). The 
y-axis displays residuals from a regression of age vs. CSF KYNA concentration (nM). 
 
 
4.1.4 Association of rs10158645 to psychosis  
The minor allele of rs10158645 was associated with psychotic symptoms in sample I 
(n=76, OR=3.98, 95% CI: 1.37-11.5, P=0.011). The effect of rs1018645 genotype on 
psychosis was also studied using a replication sample of 565 bipolar disorder patients 
without CSF KYNA data (sample II). Similar to the result from sample I, we 
observed an increased risk of psychosis in sample II for patients carrying the minor G 
allele (OR=1.50, 95% CI: 1.06-2.03; P=0.020). Using a recessive model yielded an 
OR of 6.45 (95% CI: 1.48-28; P=0.013). Combining both samples (n=641) yielded an 
OR of 1.59 (95% CI: 1.17-2.16; P=0.002) under an additive model. 
 
 
4.1.5 Association of rs10158645 with set-shifting performance  
Of the 76 patients in sample I, 51 agreed to participate in TMT testing. In the 
replication sample, with no CSF KYNA data, 38 patients had carried out TMT. To 
achieve sufficient power, we tested the effect of rs10158645 on set-shifting ability 
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using a combined sample (n=89). Carriers of the minor allele scored close to 
average (n=60, 10.1 ± 0.30), while the non-carriers (n=29) had a significantly lower 
mean contrast score (8.93±0.47, P=0.035), indicating diminished cognitive 
flexibility.  
 
 
4.1.6 Causal inference analyses proposes a mechanistic route from 
rs10158645 via KYNA and HVA to psychosis 
The minor allele in rs10158645 was also associated with increased CSF HVA 
concentration (n=72, P=7.3x10-7). We endeavored to statistically evaluate a 
mediational model with rs10158645 allele frequency as the causal variable, CSF 
KYNA as the mediator, and CSF HVA as the outcome variable. Using a non-
parametric bootstrap method (the PROCESS script for SPSS (Hayes, 2013), 
percentile bootstrap=20000), the indirect effect that estimates the amount of 
mediation was significant (point estimate=64.8, 95% bootstrap CI: 35.7-101), while 
the direct (direct effect=total effect–indirect effect) was smaller and non-significant 
(point estimate=42.6, 95% bootstrap CI:-0.53-85.7). To study possible reverse causal 
effects we interchanged the mediator and outcome variable. This suggested a better fit 
of the first model. These mediation analyses therefore propose that the causal minor 
allele in rs10158645 increases CSF HVA via KYNA, in agreement with previous 
experimental studies. 
 
To study whether the effect of KYNA on psychosis in bipolar disorder was driven by 
its effect on dopaminergic transmission, we tested a mediation model in which CSF 
KYNA was the causal variable, CSF HVA the mediator, and psychosis the outcome 
variable. Again, we used PROCESS with percentile bootstrap (20000), age as a 
covariate, and the same 72 subjects. This model gave a significant indirect effect 
(point estimate=0.71, 95% bootstrap CI: 0.15-1.81) with a non-significant direct 
effect (point estimate=0.15, 95% bootstrap CI: -0.61-0.90), suggesting that the 
increased risk of psychosis caused by elevated levels of KYNA was mediated by 
dopamine neurotransmission. Numerous studies link KYNA to dopaminergic 
signaling. KYNA has also previously been shown to associate to psychosis in a 
clinical sample (Olsson et al., 2012a) and is repeatedly reported to be elevated in 
Results and Discussion 
 60 
patients with schizophrenia (Erhardt et al., 2001a; Linderholm et al., 2012; Nilsson et 
al., 2005; Schwarcz et al., 2001). This is however the first time that KYNA is 
implicated in a putative chain of events, leading from a gene variant to psychosis. The 
identification of the genome significant SNP, rs10158645, associated both to levels of 
KYNA and to psychosis, made it possible for us to utilize causal inference analyses, 
trying to dissect the path leading from genotype to psychosis. These analyses suggest 
a path starting with the gene variant, leading to elevated levels of KYNA, which in 
turn leads to an increase in dopamine neurotransmission, directly underlying the 
presence of positive psychotic symptoms. Furthermore rs10158645 was also 
associated to set-shifting performance, known to be impaired in patients with bipolar 
disorder (Bora et al., 2009; Yatham et al., 2010). Even though GWAS’s aiming at 
identifying genetic variation underlying bipolar disorder and schizophrenia are 
proposing SNPs at a rapid pace, verifying the role of a gene variant associated to the 
heterogeneous cluster of symptoms present in psychotic disorders have proven 
exceptionally challenging. Since the goal of the GWAS in this study was identifying 
variation underlying the levels of KYNA, already proposed to constitute a component 
in the development of psychosis, further exploration of putative biological pathways 
might be less complex.  
 
 
4.1.7 Functional consequences of gene expression of the rs10158645 
genotype 
In order to study the effect of the rs10158645 genotype on gene expression, fibroblast 
data from the Matched Co-Twin Analysis (Nica et al., 2011), was searched regarding 
an effect of rs10158645 genotype on gene expression (by default set to a search of +/- 
1Mb, i.e., cis-effects). This revealed a significant association between the minor allele 
in rs10158645 and decreased expression of the nearby gene SNX7 (P=2.0x10-4). A 
similar and significant association (P=0.0096) was also found in a replicate sample 
(unrelated subjects of the HapMap3 populations; n=198), based on data from 
lymphoblastoid cell lines.  
 
rs10158645 is located in an intron of RP5-896L10.1, a long non-coding RNA 
(lncRNA) gene that is predominately expressed in the brain, and approximately 2 kB 
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from a predicted enhancer region (http://encodeproject.org/ENCODE/). Although 
sparsely studied, lncRNA have recently been shown to regulate the expression of 
nearby genes, i.e., cis-effects (Lai et al., 2013), suggesting that the observed cis-effect 
of rs10158645 on SNX7 was mediated by increased RP5-896L10 expression. Against 
this background, we deemed that the most likely functionality of the locus identified 
in the GWAS was in relation to SNX7. 
 
 
4.1.8 Downregulation of SNX7 induces caspase-8  
The SNX family proteins contain a phox (PX)-homology domain that binds 
phosphoinositides, and function in diverse intracellular trafficking and signaling 
processes (Teasdale and Collins, 2012). SNX7, together with SNX1,-2,-4,-5,-6 and -
8, belongs to the PX-BAR subfamily that all have a C-terminal BAR domain in 
common, and the structurally predicted phosphoinositide specificity for SNX7 is 
phosphatidylinositol 3-phosphate (PtdIns3P) (Teasdale et al., 2012). Although SNX7 
is rarely studied, a recent report showed that a down-regulation of SNX7 increases 
caspase-8 protein levels in hepatocytes, most likely by inducing the degradation of the 
short form of C-FLIP at the riboptosome platform (Xu et al., 2012). Supporting a 
functional link between SNX7 and caspase-8 in brain tissue, we found a strong 
inverse coexpression of SNX7 and CASP8 (r=-0.44; P=1.6x10-14) in DLPFC by 
utilizing 272 postmortem human brain samples. 
 
 
4.1.9 Caspase-8 and IL-1β are associated with psychosis in bipolar 
disorder 
In microglia, caspase-8 is reported to cleave pro-IL-1β into its biologically active 
structure (Burguillos et al., 2011, Dupaul-Chicoine and Saleh, 2012). To test the 
relevance of caspase-8 induced activation of IL-1β for psychotic symptoms in bipolar 
disorder, we first studied brain DLPFC CASP8 mRNA expression in a postmortem 
sample of 105 bipolar disorder patients. This revealed that CASP8 expression was 
significantly increased in bipolar disorder with psychotic features compared to bipolar 
disorder without psychotic features with an approximate fold change of 1.15 (99%CI: 
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1.04-1.20). Secondly, we re-analyzed a sample of 27 male euthymic bipolar disorder 
patients and 30 male healthy controls with regard to CSF IL-1β data (Söderlund et al., 
2011; sample III). Both the psychotic and the non-psychotic bipolar disorder group 
had significantly higher CSF IL-1β concentrations compared to controls (P<1x10-6 
and P=5.8x10-5 respectively). However, the psychotic bipolar disorder group also had 
significantly higher CSF IL-1β concentration compared to non-psychotic bipolar 
disorder patients (P=0.020). Figure 5A). The control group was significantly younger 
than the patient group (40.9±2.34 years vs. 25.4±1.31 years, P<1.0x10-6). CSF IL-1β 
concentration was, however, not associated with age, and adjusting for age gave 
similar results (data not shown). Sex, BMI, smoking status, and weekly alcohol 
consumption were not associated with CSF IL-1β concentration (data not shown). 
Comparison of pharmacological treatments between the patient groups suggested an 
equal distribution, and no significant effects of any pharmacological treatments on IL-
1β concentration could be detected.  
 
 
4.1.10 IL-1β is associated with set-shifting ability in bipolar disorder  
Bipolar disorder patients with available CSF IL-1β data (sample III) were asked to 
carry out TMT. Of 16 participating patients, 9 scored ≥10 on the TMT contrast score, 
while 7 scored <10. The median CSF IL-1β concentration was significantly higher in 
patients with more difficulties in set-shifting, defined by a score <10, compared to 
patients scoring ≥10 (P=0.012; Figure 5B). A putative influx of peripheral IL-1β to 
the brain may influence central levels of IL-1β. Thus, to avoid uncontrolled 
confounding by peripheral inflammation we also measured serum high-sensitive CRP 
(hsCRP). hsCRP covaries with serum concentration of IL-1β (Hung et al., 2011) and 
is associated with cognitive impairment (Hoshi et al., 2010). Partial correlation 
analyses with hsCRP as covariate were performed to test for a possible confounding 
effect of peripheral inflammation, but there was still a significant negative correlation 
between CSF IL-1ß concentration and set-shifting ability (rs[Spearman]=-0.59, 
P=0.021; Figure 5C). 
 
IL-1β has previously been reported to be elevated in patients with both bipolar 
disorder and schizophrenia (Söderlund et al., 2009, 2011). The cause of the increased 
IL-1β levels in CSF of patients with psychotic disorders has however not been 
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thoroughly investigated on the molecular level, and is a constant topic for speculation. 
The proposed path linking the gene variant identified in the GWAS with the function 
of SNX7, and further to caspase-8 and IL-1β constitutes one of the first plausible 
examples of molecular events leading to the increase of IL-1β in psychotic disorders. 
IL-1β has also previously been implicated in memory function. Constitutively 
expressed low levels of IL-1β has been shown to play a role in the synaptic plasticity 
in the healthy brain, as it is necessary for development of LTP (Schneider et al., 
1998). However, overexpression of IL-1β in the hippocampus of mice leads to 
deficits in spatial memory (Moore et al., 2009).   
 
Altogether, and in conformity with the previously presented data for KYNA, these 
results further strengthen the role for the involvement of IL-1β in both psychosis and 
cognition. 
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Figure 5. CSF concentrations of IL-1β euthymic bipolar disorder patients and healthy 
controls. (A) Mean ± SEM CSF IL-1β in 30 healthy male volunteers (0.79±0.044 pg/ml), 16 
bipolar disorder (bipolar disorder) patients without a history of psychosis (3.06±0.58 pg/ml), 
and 11 bipolar disorder patients with a history of psychosis (5.35±0.71 pg/ml). One-way 
ANOVA with Tukey post hoc tests; controls vs. non-psychotic bipolar disorder, P=5.8x10-5, 
controls vs. psychotic bipolar disorder, P<1x10-6, and non-psychotic bipolar disorder vs. 
psychotic bipolar disorder, P=0.020. (B) 16 of these bipolar disorder patients carried out the 
trail making test (TMT). 9 patients scored 10 or above on the contrast score and 7 scored 
below 10. The median CSF IL-1ß concentration was higher in the group that scored <10 
(5.84±2.89 [IQR] pg/ml) compared to the group that scored 10 or above (1.96±2.68 nM; 
Mann-Whitney U test, P=0.012). (C) A possible confounding effect of peripheral 
inflammation was assessed with correlation analyses. Increasing CSF IL-1ß concentration 
was associated with difficulties in set-shifting (rs = -0.53, P=0.034), also when adjusting for 
hsCRP concentration (rs = -0.59, P=0.021). Error bars represent mean ± SEM in 5A and in 5B 
the median and third quartile. Statistical significance set to P<0.05. *P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001. 
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Figure 6. Immunofluorescent staining of the astrocyte markers GFAP at 40X magnification 
(a), S100B, at 40X magnification (b) and Vimentin at 20X magnification (d) Cells did not 
stain for the neuronal marker NeuN (c) or the microglial marker Iba1 (e), confirming the 
relative purity of the cultures. All immunofluorescent staining were combined with the 
nuclear stain DAPI. 
 
 
4.1.11 IL-1β induces TDO in human cortical astrocytes 
Although it is well established that the pro-inflammatory cytokine interferon (IFN)-γ 
is a potent inducer of the kynurenine pathway, less is known about the specific effects 
of IL-1β. We therefore investigated whether IL-1β also activates the kynurenine 
pathway by inducing the rate-limiting enzymes indoleamine 2,3-dioxygenase 1 
(IDO1) and/or tryptophan 2,3-dioxygenase-2 (TDO2), hereby accounting for the 
observed increase in CSF KYNA in bipolar disorder. Fetal human cortical astrocytes 
were cultured and stimulated with recombinant human IL-1β (10 ng/ml). IFN-γ (200 
ng/ml) was used as positive control.  
 
Prior to experiments the relative purity of cultures was established. Cells hence 
expressed the astrocyte markers GFAP (Figure 6a), S100B (Figure 6b), and Vimentin 
(Figure 6d). No expression of the neuronal marker NeuN (Figure 6c), or the 
microglial marker Iba1 (Figure 6e), was detected. 
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Stimulation with IL-1β (10 ng/ml) or IFN-γ (200 ng/ml) for 24 hours increased the 
expression of IDO1 mRNA (P<0.0001) compared to vehicle treated cells (vehicle at 1 
hour standardized to 100%; Figures 7A, 7B). Stimulation with IL-1β (10 ng/ml), 
increased the expression of TDO2 mRNA (P<0.0001), while IFN-γ (200 ng/ml) did 
not (P=0.40), vehicle at 1 hour standardized to 100%; Figures 7C, 7D). 
 
 
Figure 7. mRNA levels of IDO1 and TDO2 in fetal human cortical astrocytes stimulated with 
IL-1β and IFN-γ. IDO1 and TDO2 were normalized to HPRT. Bar graphs represent IDO1 and 
TDO2 mRNA levels expressed as % of vehicle treated control cultures, where vehicle at 1hr 
=100%. A. IL-1β stimulated the induction of transcription of IDO1 (2213±198% vs. vehicle 
116±29%, P<0.0001) B. IFN-γ was only able to stimulate IDO1 transcription 
(551944±24844% vs. 116±65%, P<0.0001), C. IL-1β stimulated the induction of 
transcription of TDO2 (559±41% vs. vehicle 86±6.48%, P<0.0001), IFN-γ did not induce the 
transcription of TDO2  (63±5.71% vs. 86±6.48%, P=0.40). Data are reported as mean±SEM 
Statistical significance set to P<0.05. *P<0.05, **P<0.01, ***P<0.001. 
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Protein levels of IDO1 and TDO2 were analyzed by Western Blotting at baseline and 
after exposure to IL-1β (10 ng/ml) or IFN-γ (200 ng/ml) for 48 hours. Low levels of 
IDO1 protein expression were detected in unstimulated cells, but despite the marked 
increase of IDO1 mRNA levels following IL-1β stimulation, no changes in protein 
levels were observed after 48 h IL-1β exposure (P=0.41; Figure 8A). Stimulation 
with IFN-γ (200 ng/ml) was associated with a marked increase in IDO1 protein levels 
(P=0.001; Figures 8A). TDO2 protein expression was readily detectable at all time-
points including baseline. Stimulation with IL-1β (10 ng/ml) for 48 hours increased 
protein levels of TDO2 compared to vehicle treated cells (P=0.006; Figure 8B), 
whereas stimulation with IFN-γ (200 ng/ml) did not affect protein levels of TDO2 
(P=0.21; Figure 8B). 
 
Figure 8. Protein levels of IDO1 and TDO2 in fetal human cortical astrocytes stimulated with 
IL-1β and IFN-γ. IDO1 and TDO2 immunopositive bands are normalized to β-actin. Bar 
graphs represent IDO1 and TDO2 protein levels expressed as % of vehicle treated control 
cultures. Data are reported as mean±SEM. Representative Western blots of IDO1 and TDO2 
are shown below each bar graph. (A) Low levels of IDO1 protein expression were detected in 
unstimulated cells, but following 48 h IL-1β stimulation, no changes in protein levels were 
observed (90 ± 5.13% vs. 100 ± 7.85%; P=0.41). Stimulation with IFN-γ was associated with 
a marked increase in protein levels of IDO1 (1084 ± 117% vs. 100 ± 7.85%; P=0.001). (B) 
Stimulation with IL-1β for 48 hours increased protein levels of TDO2 compared to vehicle 
treated cells (139 ± 11.1% vs. 100 ± 2.70%, P=0.006), whereas stimulation with IFN-γ did 
not affect protein levels of TDO2 (80 ± 11.2% vs. 100 ± 8.70%; P=0.21). Statistical 
significance set to P<0.05. *P<0.05, **P<0.01, ***P<0.001, 
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Protein expression was also visualized using immunofluorescence techniques. In 
agreement with the Western Blot data, TDO2 following IL-1β exposure appeared to 
be localized in scattered cells expressing high levels of the protein (Figure. 9A), while 
IDO1 staining was weak (Figure 9B). Although IDO1 and TDO2 perform the same 
enzymatic function, they show little sequence and structure homology and are likely 
to perform the oxidative cleavage reaction using different mechanisms (Batabyal and 
Yeh, 2007). It is therefore not surprising to find that the enzymes are regulated by 
different stimuli. 
 
A       B 
 
Figure 9. Protein levels of TDO and IDO visualized using immunofluorescence, captured 
at 40X magnification.  
 
 
4.1.12 IL-1β induces the production of KYNA from human cortical 
astrocytes 
KYNA was analyzed at 1, 3, and 24 hours. At 24 hours, cells stimulated with IL-1β 
showed 4 times higher KYNA concentrations compared to vehicle treated cells 
(P<0.0001; Figure 10A). Cells stimulated with IFN-γ had >85 times higher KYNA 
concentrations compared to vehicle treated cells (P<0.0001; Figure 10B). The 
increase in KYNA levels following IL-1β stimulation might seem high in relation to 
the relatively modest increase in TDO2 protein. However, the TDO2 enzyme is a 
homotetramer reliant on heme as a prosthetic group. TDO2 enzyme activity is 
therefore not solely dependent on the abundance of protein as measured by western 
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blot, since both the assembly of the tetramer as well as the activation of the heme 
moiety will influence enzyme activity (Li and James, 2007; Ren and Correia, 2000). 
Altogether, our in vitro data suggest that IL-1β induces TDO2, resulting in elevated 
levels of KYNA. This mechanism may critically contribute to the activation of the 
kynurenine pathway as seen in several disorders. In fact TDO, but not IDO, 
expression, is elevated in patients with schizophrenia and bipolar disorder, along with 
elevated levels of kynurenine (Miller et al., 2004, 2006), suggesting that these results 
mirror the clinical situation. Also in line with these results are a lack of findings of 
elevated levels of IFN-γ in the CSF of patients with schizophrenia (Miller et al., 2011) 
 
In summary, results from this study suggest a molecular pathway, leading from 
rs10158645 affecting the function of SNX7, in turn activating capase-8 that cleaves 
pro-IL-1β into mature functional IL-1β. IL-1β in turn induces TDO, leading to 
increased production of KYNA, that in turn modulates dopamine neurotransmission, 
known to contribute to the development of psychosis and cognitive deficits 
accompanying psychotic states. 
 
 
Figure 10. Kynurenic acid levels in fetal human cortical astrocytes stimulated with IL-1β and 
IFN-γ. Fetal cultured human cortical astrocytes stimulated with recombinant human IL-1β (10 
ng/ml) and interferon (IFN)-γ (200 ng/ml). All cells were analyzed at time-points 1, 3, and 24 
hours. Bar graphs represent % of vehicle (t=1h) at these time points. Experiments were 
performed in triplicate and repeated twice. Data are shown as mean±SEM. (A) At 24 hours, 
cells stimulated with IL-1β showed 4 times higher KYNA concentrations (1.70 ± 0.11 nM) 
than vehicle treated cells (0.42 ± 0.10 nM, P<0.0001). (B) At 24 hours, cells stimulated with 
IFN-γ had more than 85 times higher KYNA concentrations (10.8 ± 0.34 nM) than vehicle 
treated cells (0.14 ± 0.04 nM, P<0.0001). Statistical analyses: one-way ANOVA with 
Bonferroni post hoc tests. All P-values are two sided. Statistical significance set to P<0.05. 
*P<0.05, **P<0.01, ***P<0.001 
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4.2 PAPER II 
Numerous studies show elevated levels of KYNA as well as kynurenine in the CSF 
and brain of patients with psychotic disorders (see introduction). In this study we 
aimed to investigate the CSF levels of QUIN, the main metabolite of the other branch 
of the kynurenine pathway, in patients with chronic schizophrenia. 
 
Age was correlated to QUIN levels in controls (P=0.012) but not in patients, there 
was however a trend towards a correlation also in patients (P=0.113). Sex, height, 
weight, and BMI were not correlated to CSF QUIN in patients or in controls. In the 
patient group there was no correlation between CSF QUIN and psychiatric symptom 
ratings (BPRS and GAF) however, there was a tendency of a positive correlation 
between CSF QUIN and serum levels of olanzapine (ρ=0.414, P=0.062). There was 
no correlation between CSF QUIN levels and CSF olanzapine levels (ρ=0.333, 
P=0.140). The mean CSF QUIN concentration did not differ between smokers/non-
smokers or male/females, in patients or in controls. (Table 2).  
 
 Smoking Sex Case 
 Yes No Male Female Patient Control 
N 12 34 30 17 21 26 
QUIN(mean±SEM) 16.5±1.8 20.5±1.0 19.2±1.3 19.4±1.0 20.6±1.5 18.2±1.1 
P-value 0.074 0.913 0.198 
Table 2. QUIN levels in patients and controls and according to sex and smoking status. 
 
 
4.2.1 No difference in QUIN, but a decreased QUIN/KYNA ratio in 
patients with schizophrenia compared to controls 
The mean CSF QUIN concentration did not differ significantly between patients 
and controls (P=0.198; Figure 11A). Adjusting the comparison for potential 
confounding by age and sex gave a similar result (OR=0.93, 95% CI 0.80-1.10; 
P=0.355). The QUIN/KYNA ratio was however close to significantly decreased in 
patients compared to healthy controls (P=0.057; Figure 8B). Adjusting the 
analysis for differences in age and gender distribution in two groups strengthened 
the association between the patient group and a decreased QUIN/KYNA ratio 
Magdalena Kegel 
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(OR=0.66, 95% CI 0.45-0.95; P=0.027). This result is likely to be independent of 
smoking status. The QUIN/KYNA ratio was higher in patients despite the fact that 
there was a nearly significant positive correlation between serum olanzapine and 
QUIN (ρ=0.414, P=0.062). 
 
   A                     B 
 
 
Figure 11. (A) Mean ± SEM CSF QUIN levels in patients with schizophrenia (20.6 ± 
1.51 nM) and healthy controls (18.2 ± 1.08 nM; P=0.198). Following adjustment for age 
and sex OR=0.93, 95% CI 0.80-1.10; P=0.355 (B) the QUIN/KYNA ratio in patients with 
schizophrenia and healthy controls. Following adjustment for age and sex OR=0.66, 95% 
CI 0.45-0.95; P=0.027. 
 
 
4.2.2 Relationship between tryptophan and its metabolites 
A correlation between CSF QUIN and CSF kynurenine levels was detected in 
patients (ρ=0.53, P=0.014) but not in the controls (ρ=-0.32, P=0.117). A similar 
pattern was seen regarding CSF QUIN and CSF KYNA in patients (ρ=0.54, 
P=0.016) and in controls (ρ=0.12, P=0.565). No significant correlation between 
CSF tryptophan and CSF QUIN levels was detected in patients (ρ=0.32, P=0.164), 
or in controls (ρ=-0.18, P=0.373). See Table 3 for levels of kynurenine, KYNA 
and tryptophan. The fact that the correlation between QUIN on one hand and 
KYNA and KYN on the other hand was observed only in patients is indicating that 
the kynurenine pathway is upregulated in the patient group. Despite a correlation 
on the individual patient level, no difference in CSF QUIN levels between patients 
and controls was observed, suggesting that a putative enhancement of QUIN 
formation is substantially lower compared to the increase in kynurenine and 
KYNA in the patients. The lack of correlation between CSF QUIN and CSF 
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tryptophan might be attributed to the fact that no difference in the levels of neither 
tryptophan nor QUIN was observed. 
  
 Patient Control 
N 21 26 
tryptophan (µM) 1.7±0.03 1.8±0.07 
N 21 26 
kynurenine (nM) 57.2±3.5 37.3±4.3 
N 19 26 
KYNA        (nM) 2.1±0.2 1.6±0.1 
Table 3. CSF levels of tryptophan, kynurenine and KYNA in the present sample, 
presented as mean ± SEM. Part of these data have previously been published (Linderholm 
et al., 2012). 
 
The higher QUIN/KYNA ratio in controls is in line with one previous study 
investigating levels of QUIN in post mortem brain of patients with schizophrenia 
(Schwarcz et al., 1988). Previous studies provide a mechanistic explanation for this. 
Thus, compared to the higher capacity of KAT enzymes, displaying Km values in the 
low millimolar range (Okuno et al., 1991), the KMO enzyme gets saturated at 
relatively low concentrations (Km≈20 µM; Bender and McCreanor, 1985), and can 
therefore act as a rate limiting step in the synthesis of QUIN. In a situation where L-
kynurenine is elevated (e.g. by induction of TDO) such a limitation of KMO might 
guard against excessive production of QUIN. A suboptimal function of KMO could 
also present an explanatory mechanism of the observed increase in KYNA but not in 
QUIN (Holtze et al., 2012b; Lavebratt et al., 2014; Sathyasaikumar et al., 2011). Such 
a scenario would thus shunt the metabolism of L-kynurenine towards formation of 
KYNA, which indeed is observed in the present study. This study therefore renders 
support to the hypothesis that KYNA is elevated in patients with schizophrenia, likely 
due to a lower input of kynurenine into the QUIN branch of the pathway.  
 
In summary, the present findings indicate an over-activated but also an imbalanced 
kynurenine pathway in patients with schizophrenia, favoring the production of KYNA 
over QUIN.  
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4.3 PAPER III 
4.3.1 Detection of transcripts encoding kynurenine pathway enzymes  
All the investigated kynurenine pathway transcripts (IDO1, TDO, KAT1, KAT2, 
KAT3, KAT4, KMO, KYNU, HAAO, QPRT) were detected in untreated fibroblast 
cell cultures. The levels of expression varied considerably across the different genes, 
with transcripts encoding IDO1 detected at the lowest level and those encoding KAT3 
detected at the highest level. The variation across individual cultures (n=7), ranged 
from 2.5 (KAT3) to 145-fold (KYNU). 
 
This is the first report that human skin fibroblast in culture express detectable levels 
of transcripts encoding the different enzymes of the kynurenine pathway. Substantial 
differences in the basal levels of expression across genes and individuals were 
observed which are likely to be explained by genetic and epigenetic variation between 
individual cultures. 
 
4.3.2 Modulation of transcript-levels by IFN-γ and/or TNF-α  
The levels of transcripts encoding IDO1 were significantly increased (>105-fold) in 
cultures stimulated with IFN-γ (P<0.001) as well as IFN-γ together with TNF-α 
(P<0.001) compared to unstimulated cultures, although no effect of TNF-α alone was 
observed (Figure 12A). Transcripts encoding tryptophan 2,3-dioxygenase (TDO), on 
the other hand, were significantly down-regulated in cultures stimulated with a 
combination of IFN-γ and TNF-α (20-fold; P<0.001), as compared to unstimulated 
cells or cells stimulated with the individuals cytokines (Figure 12B). Moreover, levels 
of transcripts encoding the kynurenine aminotransferases (KATs) were either 
unaffected (KAT2) or down-regulated (KAT1 and KAT3) following stimulation with 
a combination of IFN-γ and TNF-α (2.6- fold, P<0.001 and 1.7-fold, P<0.01 
respectively, Figure 12C, D and E). Levels of transcripts encoding mitochondrial 
aspartate aminotransferase (mitAAT, i.e KAT4) were significantly down regulated 
(1.5-fold) in cultures treated with IFN-γ (P<0.05) and further decreased with the 
combination of IFN-γ and TNF-α (2.7-fold; P<0.001, Figure 12F). Levels of 
transcripts encoding kynurenine 3-monooxygenase (KMO) observed in the fibroblast 
cultures were not significantly affected by the cytokine treatment (Figure 12G). 
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Levels of transcripts encoding kynureninase (KYNU) were upregulated following 
IFN-γ (8-fold; P<0.01) or TNF-α stimulation (28-fold; P<0.001). A further increase 
in the levels of KYNU transcripts was observed with the combination of IFN-γ and 
TNF-α (650-fold; P<0.001, Figure 12H). Levels of transcripts encoding 3-
hydroxyanthranilate 3,4-dioxygenase (HAAO) were upregulated only in cultures 
treated with the combination of IFN-γ and TNF-α (12-fold, P<0.001, Figure 12I). 
Levels of transcripts encoding quinolinate phosphoribosyltransferase (QPRT) were 
down-regulated by the combination of IFN-γ and TNF-α (5-fold, P<0.001), but 
unaffected by the individual cytokines (Figure 12J). 
 
In line with previous studies (Byrne et al., 1986; Däubener and MacKenzie, 1999), 
human fibroblast cultures appear to be able to increase the rate of tryptophan 
degradation along the kynurenine pathway in response to IFN-γ stimulation, with a 
further increase when applying IFN-γ and TNF-α simultaneously. Our present 
findings support the notion that IDO1 is the major determinant of this response in 
human fibroblasts, as is also the case in many other cell types (King and Thomas, 
2007). 
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Figure 12. Relative levels of transcripts encoding enzymes in the kynurenine pathway (A-J) 
following treatment with IFN-γ (200 U/ml), TNF-α (100 U/ml) or the combination of these 
two cytokines (IFN-γ+TNF-α) during 48 hrs in serum-free cell culture medium (n = 7). 
Levels of all transcripts are normalized to levels observed in untreated control cells (base-
line). *P<0.05, **P<0.01, ***P<0.001. 
 
To address potential functionality of the kynurenine pathway in these human 
fibroblast cultures, we measured the accumulation of KYNA, one of the end 
metabolites of the pathway in the supernatants. Significantly higher levels were 
detected in supernatants of cells treated with IFN-γ or with IFN-γ and TNF-α 
compared to supernatants from unstimulated cells (P<0.0001; Figure 13). TNF-α 
alone did not cause a significant increase in the accumulation of KYNA. 
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In summary, the present results suggest that fibroblast cultures can be used to study 
disease-related abnormalities in the kynurenine pathway of tryptophan degradation. 
However, in order to extrapolate data from experiments in dermal fibroblasts to 
mechanisms in the CNS, further validation of this model is needed. 
 
 
 
Figure 13. Levels of KYNA at baseline and following stimulation with IFN-γ and TNFα, 
alone or in combination. KYNA was significantly increased following stimulation with IFN-γ 
(27.2 ± 18 nM, P=0.01), as well as following stimulation with a combination of IFN-γ and 
TNF-α (39.8 ± 20.1 nM; P=0.0003) compared to baseline levels (3.4 ± 0.6 nM). All P-values 
are two sided. Statistical significance set to P<0.05. *P<0.05, **P<0.01, ***P<0.001 
 
 
4.4 PAPER IV 
4.4.1 Differences in CSF metabolites and cytokine levels between MZ 
and DZ twins 
No difference was observed in the variance of any metabolite between MZ and DZ 
pairs (Table 4A). There was no difference in any of the investigated metabolites 
between probands and co-twins (Table 4B). There was however a trend towards 
higher levels of CSF KYNA, adjusted for smoking, in probands than in co-twins 
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(P=0.059). We could not detect any systematic difference in CSF metabolite levels 
between twin pairs in the MZ group compared to the DZ group (Figure 14).  
The lack of systematic differences might be attributed to the fact that the sample is too 
small to detect any such differences. However, the relatively large difference in 
several CSF metabolites observed in individual MZ twin pairs, principally indicate 
that regulation of these metabolites partly is a result of environmental components. 
Hence, our findings are in consonance with the general view that the 
pathophysiological underpinnings of psychotic disorders also reflect a functional 
environmental constituent. Thus, the present results may contribute to our knowledge 
on gene-environment interactions in psychotic disorders. 
 
Table 4 A) Difference of CSF metabolite and cytokine levels between proband and co-twin in 
5 MZ and 5 DZ pairs using Mann-Whitney U-test. Values represent absolute difference 
between proband and co-twin and are presented as mean ± SEM. B) CSF levels of 
metabolites and cytokines in probands and co-twins computed using Mann Whitney.  
 
  
A           B 
 MZ 
Mean 
difference 
DZ 
Mean 
difference 
P Proband n=10 
Co-twin 
n=13 P 
KYNA (nM) 2.1±0.6 5.0±2.8 0.690 5.8±1.6 2.9±0.4 0.115 
QUIN (nM) 29.3±11.0 8.6±2.3 0.690 32.1±6.3 31.2±8.6 0.693 
TRP (µM) 0.4±0.2 1.3±0.7 0.310 2.6±0.4 1.9±0.1 0.166 
5-HIAA (nM) 41.9±16.1 36.8±20.2 0.548 94.1±12.6 81.6±10.4 0.446 
HVA (nM) 39.2±15.2 55.2±25.2 1.000 125.5±18.8 101.1±12.8 0.284 
IL-6 (pg/ml) 1.3±0.82 0.3±0.04 0.548 1.22±0.16 1.46±0.43 0.927 
IL-8 (pg/ml) 8.0±5.6 6.9±1.7 0.421 28.2±4.9 29.7±6.0 0.879 
TNF (pg/ml) 0.08±0.05 0.06±0.02 0.548 0.25±0.03 0.24±0.05 0.232 
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Figure 14. CSF levels of KYNA, QUIN, TRP, HVA, 5-HIAA, IL-6, IL-8 and TNF-α in 
probands and co-twins displayed for MZ and DZ pairs.  
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4.4.2 Correlations between CSF metabolites and cytokines 
There was a correlation between CSF levels of IL-8 and CSF QUIN (rho=0.481, 
P=0.020), CSF IL-8 and CSF TRP (rho=-0.617, P=0.002), CSF KYNA and CSF 
HVA (rho=0.577, P=0.004), CSF KYNA and CSF 5-HIAA (rho=0.660, P=0.001), 
and a nearly significant correlation between CSF TRP and TNF-a (rho=-0.41, 
P=0.051). 
 
These findings that are in line with previous data showing correlations between 
KYNA, HVA and 5-HIAA, (Nilsson-Todd et al., 2007; Nilsson et al., 2007), as well 
as a link between inflammatory signaling and the kynurenine pathway (Mándi and 
Vécsei, 2012), are illustrating the notion that immune signaling, tryptophan 
breakdown pathways and dopamine neurotransmission are linked. All of these 
components are also separately (and in combination) implicated in psychotic 
disorders. 
 
 
4.4.3 Relation of levels of CSF metabolites and cytokines to 
psychometric rating scales 
Analyzing the levels of the individual metabolites in relation to the psychiatric 
rating scales revealed an association of CSF KYNA, adjusted for smoking, to total 
SCID-II score (P=0.018) and to total SPQ-B score (P=0.049). CSF HVA, adjusted 
for neuroleptic use, was associated to total SCID-II score (P=0.007), to total SAPS 
score (P=0.003) and to total SANS score (P=0.024). 5-HIAA, adjusted for use of 
antidepressant medication, was associated to total SCID-II score (P=0.002) and to 
total SPQ-B score (P=0.010), total SANS score (P<0.001) and total SAPS score 
(P=0.001). CSF QUIN, when adjusted for CSF albumin levels, was associated to 
total SPQ-B score (P=0.027). No other kynurenines or cytokines were associated to 
any of the rating scales (See Table 5).  
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4.4.4 KYNA, HVA and 5-HIAA associations with sub-ratings  
Since the total score for SCID-II in our analysis consisted of the sub-ratings for 
paranoid, schizoid and schizotypal personality disorder (cluster A), an analysis of 
the sub-ratings revealed an association of CSF KYNA with schizotypal personality 
(P=0.013) but not schizoid (P=0.103). There was a trend towards an association 
between CSF KYNA and the paranoid sub-scale (P=0.062). The associations 
between levels of CSF HVA and sub-ratings of SCID-II were significant for all 
three parts, i.e. paranoid (P=0.013), schizoid (P=0.006) and schizotypal (P=0.020). 
5-HIAA was associated to the subrating for schizotypal (P=0.035), but not for the 
paranoid and schizoid personality disorders. 
 
 SPQ-B  SCID-II  
 Estimate (95%CI) P Estimate (95%CI) 
 
P Co-factor 
KYNA 
(nM) 
1.048 (1.000-1.099) 0.049* 1.082(1.015-1.153) 0.018* Smoking 
QUIN 
(nM) 
1.051 (1.006-1.098) 0.027* 1.001 (0.928-1.079) 0.982 CSF Albumin 
TRP 
(µM) 
1.007 (0.980-1.034) 0.606 1.008 (0.978-1.039) 0.588 None 
5-HIAA 
(nM) 
1.043 (1.012-1.075) 0.010* 1.083 (1.036-1.113) 0.002** Antidepressant  
HVA 
(nM) 
1.033 (0.998-1.069) 0.066 1.066 (1.020-1.114) 0.007** Neuroleptic 
IL-6 
(pg/ml) 
0.977 (0.925-1.031) 0.377 0.994 (0.925-1.070) 0.872 Snuff 
IL-8 
(pg/ml) 
0.979 (0.956-1.002) 0.067 0.983 (0.956-1.011) 0.193 Neuroleptic 
TNF 
(pg/ml) 
0.985 (0.966-1.005) 0.127 0.985 (0.959-1.012) 0.241 Neuroleptic 
      
 SANS  SAPS   
 Estimate (95%CI) P Estimate (95%CI) P Co-factor 
KYNA 
(nM) 
1.010 (0.998-1.023) 0.562 1.019 (0.998-1.042) 0.075 Smoking 
QUIN 
(nM) 
1.008 (0.995-1.021) 0.223 1.004 (0.984-1.025) 0.647 CSF Albumin 
TRP 
(µM) 
0.997 (0.991-1.003) 0.346 0.996 (0.984-1.007) 0.455 None 
5-HIAA 
(nM) 
1.014 (1.007-1.020) <0.001*
** 
1.022 (1.010-1.033) 0.001** Antidepressant 
HVA 
(nM) 
1.014 (1.006-1.023) 0.003** 1.020 (1.003-1.037) 0.024* Neuroleptic 
IL-6 
(pg/ml) 
0.998 (0.984-1.012) 0.734 1.001 (0.986-1.015) 0.935 Snuff 
IL-8 
(pg/ml) 
0.994 (0.986-1.003) 0.187 0.999 (0.987-1.012) 0.867 Neuroleptic 
TNF 
(pg/ml) 
0.996 (0.989-1.003) 0.278** 0.992 (0.983-1.000) 0.057 Neuroleptic 
      
Table 5. Linear mixed model analysis of KYNA, QUIN, tryptophan, HVA, 5-HIAA, IL-6, 
IL-8 and TNF levels against SPQ-B, SCID-II, SANS and SAPS.  
 
The presently found associations between KYNA, HVA and 5-HIAA with measures 
of schizotypal traits in the SCID-II and SPQ-B ratings are in line with previous 
experimental and clinical observations. KYNA is thus tightly linked to dopamine 
signaling in the brain and modulates midbrain dopaminergic firing (Erhardt and 
Engberg, 2002; Linderholm et al., 2007; Olsson et al., 2009; Schwieler et al., 2004). 
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In addition experimental studies show an increased dopamine release and increased 
locomotor activity following an amphetamine challenge in rodents with centrally 
elevated KYNA levels (Olsson et al., 2009, 2012b). The levels of CSF KYNA have 
also previously been found to correlate to CSF levels of the monoamine metabolites 
HVA and 5-HIAA; (Nilsson-Todd et al., 2007; Nilsson et al., 2007). These findings 
contribute to the notion that KYNA, as well as dopamine, plays a role in psychotic 
disorders, in this context extended to sub-clinical features captured by the SCID-II 
and SPQ-B ratings.  
 
In the present study, there was a trend towards an association between KYNA and 
SAPS. All the patients were however, well medicated, and had a relatively high 
level of functioning, which might explain that the association to the SAPS score did 
not reach significance. This indicates that measures of schizotypal features might be 
more effective in detecting the traits shared between patients with psychotic 
disorder and their first-degree relatives, and thus reflect a genetic vulnerability to 
psychotic disorder. Indeed, a shared genetic basis of schizophrenia and schizotypal 
personality traits has previously been suggested (see Siever and Davis, 2004 for 
review).   
 
The positive association between HVA and SANS detected here has to our 
knowledge not been reported previously. A limitation of the present study is that our 
cohort is small and highly heterogeneous, with a proportion of patients with major 
depression. Since the SANS might also pick up traits of depressive character, we 
cannot exclude that the correlation reflects other pathogenic processes although the 
total SANS score in our sample was not high in depressed patients. On the contrary, 
CSF 5-HIAA levels, in this sample also associated to both SANS and SAPS, have 
previously been associated with suicidal behavior (Jimenez-Treviño et al., 2011). It 
would be of value to investigate the relation of specific metabolites or cytokines on 
individual items; however, in the present study such an approach was hampered by 
the sample size. Studying the similarities and differences in the associations 
between KYNA, HVA and 5-HIAA to the investigated rating scales, might reflect 
distinct disease processes connected to different neurochemical aberrations. Thus, 
specific symptoms of psychotic disorders may be reflected by distinct 
pathophysiological mechanisms.  
Results and Discussion 
 82 
 
KYNA has previously been shown to be associated to manic and psychotic features 
in individuals with bipolar disorder (Olsson et al., 2012a). In our study, the trend 
towards an association to positive symptoms using SAPS did not reach significance, 
tentatively related to lack of power as well as to the fact that all patients were well-
medicated.   
 
None of the cytokines analyzed was found to correlate to any psychometric scale. 
This may be related to the fact that the cytokine analysis was made on previously 
thawed samples. Indeed, freeze-thaw cycles are known to affect the concentration of 
cytokines in human samples(de Jager et al., 2009; Lindqvist et al., 2009; Schwieler 
et al., 2014).  
 
In conclusion, the present results indicate that the lack of a systematic differences 
between MZ-, and DZ pairs, as well as the relatively large variability within the MZ 
group, reflect a strong environmental effect upon the levels of these markers. In 
addition the present result show that CSF KYNA, CSF HVA and CSF 5-HIAA are 
associated to ratings of schizotypal personality traits in a cohort of twins with and 
without psychotic morbidity, a finding that constitutes another piece of evidence of 
the importance of KYNA in psychotic symptomatology. 
 
 
 
Magdalena Kegel 
 
 83 
5 GENERAL DISCUSSION 
Experimental and clinical evidence for an immunological component in psychotic 
disorders is amassing. Clinical research investigating neuroinflammation and immune 
signaling in psychotic disorders show elevated levels of the cytokines IL-1β and IL-6 in 
patients with schizophrenia and bipolar disorder (Garver et al., 2003; Sasayama et al., 
2013; Schwieler et al., 2014; Söderlund et al., 2009, 2011). GWAS efforts in 
schizophrenia contribute to this picture by repeatedly reporting hits in the MHC region 
(Jia et al., 2011; Ripke et al., 2014; Stefansson et al., 2009). The activation of the 
kynurenine pathway, being critically regulated by the immune system, may directly 
convey immune signaling to glutamatergic, cholinergic and dopaminergic 
neurotransmission, hereby linking the view of an inflammatory component of 
schizophrenia with the well established dopamine- and glutamate hypotheses of the 
disease (see Müller et al., 2011 for review).  Results from this thesis further strengthen 
the view that KYNA is a pivotal compound along the mechanistic pathways leading to 
psychosis. By performing causal inference analyses, we were able to confirm the 
association of KYNA with positive psychotic symptoms, likely induced by increased 
dopamine signaling. Furthermore, in bipolar disorder we found a genome-wide 
significant gene variant, rs10158645, which might impact the levels of KYNA 
allegedly by a previously unknown route; a decreased function of SNX7 leading to 
increased signaling through caspase-8/IL-1β. We also found that rs10158645, as well 
as both KYNA and IL-1β, associated with cognitive flexibility in the set-shifting 
paradigm, with higher levels of IL-1β and KYNA in the group with poor performance. 
The results from this thesis hence confirm prior data proposing a role for KYNA in 
psychosis and cognition, and more importantly, they also extend our knowledge on the 
signaling pathways involved (see Figure 15). 
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Figure 15. SNX7 mediated induction of the kynurenine pathway in bipolar disorder 
 
The kynurenic acid hypothesis of schizophrenia states that levels of KYNA are 
elevated in patients with schizophrenia. QUIN, representing the other, microglial, 
branch of the kynurenine pathway has been assumed to be in the range of healthy 
controls (Schwarcz et al., 1988). Whether there is a specific activation of the KYNA 
branch without activation of the microglial branch of tryptophan degradation in patients 
with psychotic disorders has been repeatedly questioned. In vitro studies using pro-
inflammatory cytokines, e.g. IFN-γ often show an equal activation of both branches of 
the pathway, and in certain disorders both QUIN and KYNA are elevated (see 
introduction). We, therefore, measured CSF levels of QUIN in patients with 
schizophrenia and in healthy controls and could confirm the picture with a selective 
activation of the KYNA branch of the kynurenine pathway. QUIN levels in patients 
were hence in the same range as in the healthy controls, and, as a result, the 
QUIN/KYNA ratio was higher in controls compared to patients with schizophrenia. 
There are several rational explanations for a specific increase in KYNA in psychotic 
disorders. Firstly, the increased activity of the kynurenine pathway might be attributed 
to increased activity of TDO, induced by IL-1β as observed in Paper I of this thesis. 
Secondly, the predominance of the KYNA branch in psychotic disorders might be 
attributed to the differences in activity of the KAT and the KMO enzymes. In contrast 
to the KAT enzymes, displaying Km values in the millimolar range (Okuno et al., 1991) 
the KMO enzyme gets saturated at relatively low concentrations (Km≈20 µM; Bender 
and McCreanor, 1985), and can, therefore, act as a second rate-limiting step in the 
synthesis of QUIN. In a situation were levels of kynurenine are elevated, a 
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comparatively larger proportion of kynurenine is converted to KYNA, unless 
downstream enzymes, leading to QUIN, are induced as well. In psychotic disorders this 
is of particular relevance since a suboptimal function of the KMO enzyme, in conjunct 
with elevated levels of KYNA, are reported (Holtze et al., 2011; Lavebratt et al., 2014; 
Sathyasaikumar et al., 2011). The notion of KMO being indirectly responsible for 
KYNA levels is supported by experimental studies where elevated KYNA levels are 
seen in Kmo knockout mice as well as following administration of pharmacological 
inhibitors of KMO (Erhardt et al., 2001b; Giorgini et al., 2013; Speciale et al., 1996; 
Zwilling et al., 2011). However, the activity of other enzymes of the kynurenine 
pathway might also contribute to the clinically observed imbalance in kynurenine 
metabolism. For example, a disruptive mutation in KYNU, the enzyme converting 3-
HK to 3-HAA (see Figure 1) was recently identified in a study investigating rare 
mutations constituting a polygenic burden in schizophrenia (Purcell et al., 2014).  
 
In this thesis, cell culture studies were employed to study specific biological processes. 
The use of simplified in vitro models in the studies of psychiatric disorders might be 
viewed upon with skepticism, but are an invaluable compliment to clinically oriented 
research. This is specifically the case in fields where direct tissue observation 
possibilities are limited, for instance in studies involving the brain. As technical 
advancements in brain imaging are gaining new ground, such techniques hold a 
promise of large contributions to future psychiatric research. In vitro techniques can 
however provide answers that will not be accessible by other methods for decades to 
come. In this thesis, cell cultures were employed to study the kynurenine pathway, 
namely the enzymes and metabolites produced along its path. In study I, we were able 
to show that astrocytic TDO is specifically upregulated in response to IL-1β, leading to 
an increased production of KYNA. TDO, in contrast to IDO, has for long been 
considered not to be regulated by immunological stimuli. Albeit the evidence for a 
direct involvement of IDO in psychotic disorders has been scarce, IDO is the enzyme 
most frequently cited in the context of kynurenine pathway induction in psychiatric 
disorders. The reason for the negligible interest in TDO is the general view that TDO is 
not regulated by inflammatory stimuli. This assumption is however made based on a 
too general interpretation of data. TDO is hence neither induced in response to 
stimulation with the prototypical IDO inducer IFN-γ or in response to a general 
immune stimulation with endotoxins (Saito et al., 1991, 1992; Takikawa et al., 1986). 
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However, it turned out during the work with this thesis, that TDO is indeed up-
regulated in response to IL-1β. This finding is consistent with the fact that TDO-, but 
not IDO expression, is elevated in the brains of patients with schizophrenia and bipolar 
disorder (Miller et al., 2004, 2006).  
 
A drawback of our in vitro studies is that fetal astrocytes were used. Some studies point 
to the fact that fetal astrocyte populations might differ from adult populations in the 
type of surface receptors they express, and thus their responses to external stimuli 
(Lafortune et al., 1996). However, also adult astrocytes do not constitute a single 
homogenous population as it is proposed that several different subtypes of astrocytes 
exist (Álvarez et al., 2014; Castejón, 1999; Hochstim et al., 2008; Svensson and 
Brodin, 2010). Adult human astrocytes are however not easily accessible. Therefore, a 
high validity model of the kynurenine pathway, based on peripheral cells such as 
dermal fibroblasts would have a large impact on the possibilities to perform biological 
research in psychiatric disorders. During the work with this thesis, the prospect to use 
dermal fibroblasts for the study of the kynurenine pathway was hence investigated.  
Dermal fibroblasts are not only relatively easy to collect from adults, but can also easily 
be assembled from different individuals, with and without psychotic disorders. This 
introduces the opportunity to investigate differences in molecular genetics between 
patients and controls using cell culture experiments. The data presented in this thesis 
confirm that fibroblasts indeed express the entire kynurenine pathway and that the cells 
are sensitive to stimulation with proinflammatory cytokines in order to increase the 
activity of the pathway. However, many questions remain to be answered. Most 
importantly, does the response to specific cytokines resemble responses in glial cells? 
Are the relative increases in expression of specific enzymes in agreement with what we 
know from studies of microglia or astrocytes? The fibroblast model has been further 
investigated in patients with schizophrenia and bipolar disorder (Johansson et al., 
2013), but needs further validation before it can be considered a reliable model. 
Nevertheless, the results from this thesis support the view that also peripheral cell 
systems are valuable tools for research in psychiatric disorders. 
 
Based on the above mentioned complexities of cell culture experiments, it is crucial to 
take the entire context of immune signaling into consideration when designing a study 
investigating the impact of immune signaling on metabolic systems or 
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neurotransmission; the cellular source of the cytokines, the type of target cells, and 
synergistic effects by combinations of cytokines may all affect the observed results. 
Hence, results from studies using an approach with endotoxin or viral exposure will 
likely differ from studies using single cytokines as the former will illicit a general 
immune response composed of the whole array of immune components. The observed 
result will, therefore, be the sum of all these mechanistic sub-components. Studying 
single cytokines instead allows narrowing down on specific mechanisms. Both 
approaches have their strengths and weaknesses and will undoubtedly model different 
aspects of immune-brain interactions. 
 
In this thesis, data on a number of kynurenine metabolites and cytokines in twins with 
severe psychiatric disorders are presented for the first time. Twin studies have been an 
invaluable resource for investigating the impact of genes on specific phenotypes. They 
have aided in assessing heredity rates for disorders, such as schizophrenia and bipolar 
disorder, and are as valuable in exploring heredity of less complex phenotypes, such as 
levels of kynurenine metabolites. In this study we found evidence of an environmental 
impact on the levels of TRP, KYNA, QUIN, HVA, 5-HIAA, IL-6, IL-8 and TNF-α.  
 
Results presented in paper IV, further complement and support the findings of a link 
between KYNA and psychosis, in this case extended to subclinical schizotypal features 
also present in first-degree relatives of patients. These data, therefore, contribute to the 
notion that brain KYNA is a potential endophenotype for psychotic disorders. Data 
presented in this thesis indicate that non-affected family members tend to have higher 
CSF levels of KYNA than previously observed in healthy controls (Erhardt et al., 
2001a; Linderholm et al., 2012; Nilsson et al., 2007). A higher rate of the phenotype in 
non-affected family members compared to the general population is one of the criteria 
in order to consider a phenotype an endophenotype (Gottesman and Gould, 2003). 
Further studies of inheritance patterns and the expression of the phenotype in relatives 
of patients with psychotic disorders are, therefore, warranted. 
 
In all the clinical studies in this thesis, patients were treated with antipsychotic 
medication. This is indeed a problem inherent to almost all clinical research of 
psychotic disorders. The use of statistical models where medication is added as an 
explanatory variable might in part compensate for this, hence reducing the risk that 
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findings are due to medication effects. Nevertheless, in the present studies it is difficult 
to fully disregard effects of medication, and several studies show effects of 
antipsychotic medication on immune signaling (Müller et al., 1997; see Pollmächer et 
al., 2000 for review). In order to dispel any prevailing doubts about the authenticity of 
these findings further studies employing drug-naïve, and drug-free patients are needed. 
 
According to the results of this thesis, several possible pathological mechanisms 
leading to the development of psychosis may exist. It is known that a genetic 
vulnerability is the strongest risk factor for both schizophrenia and bipolar disorder. 
Culprit genes may encompass the regulation of immune signaling as was observed in 
paper I, where rs10158645 was associated with a reduced expression of SNX7. 
Disrupted immune signaling, in the form of elevated levels of specific cytokines, may 
induce TDO, hence increasing the production of KYNA. Brain KYNA then modulates 
glutamatergic, cholinergic, and, indirectly, dopaminergic neurotransmission. All these 
neurotransmitter system are implicated in the development of psychotic behavior and 
cognitive functions.  
 
The results of the present thesis add new, substantial information regarding 
pathological mechanisms leading to the development of psychotic disorders. We 
suggest a chain of immune signaling events, originating in a genetic aberration, 
affecting tryptophan metabolism and dopamine neurotransmission. This molecular 
pathway is here implicated in core symptoms of psychotic disorders like cognitive 
impairment and psychosis. Clearly, the presently revealed dysfunction of immune 
signaling may open up for novel strategies in the treatment of psychotic disorders.  
Intracellular signaling pathways are still sparsely investigated in psychotic research. 
Clinically observable changes in neurotransmission and immune signaling are however 
accompanied by, or even based on alterations in intracellular signaling pathways. The 
study of such pathways hence provides new directions in which to focus our research, 
as well as targets for new and better pharmacological interventions. 
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